Home
  >  
Section 36

EurekaMag Full Text Articles Chapter 35,488



References:

Dicenzo, R.; Fischl, M.; Collier, A.; Feinberg, J.; Forrest, A.; Ribaudo, H.; Difrancesco, R.; Morse, G.; Aactg 388/733 Protocol Team 2002: Pharmacokinetics of combined indinavir and nelfinavir. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 42: 30
Boos, J. 2000: Pharmacokinetics of conditioning regimens. Annals of Hematology 79(Suppl 2): S9
Sinegubova, Y.V.; Ryabov, V.V.; Ivanovskaya, E.A.; Karpova, T.R.; Markov, V.A. 2000: Pharmacokinetics of cordanum in its peroral administration to patients with acute myocardial infarction. Khimiko-Farmatsevticheskii Zhurnal 34(4): 9-10
Morikawa, N.; Mori, T.; Kawashima, H.; Abe, T.; Takeyama, M.; Kobayashi, H. 2001: Pharmacokinetics of cyclophosphamide and etoposide in plasma and cerebrospinal fluid during high dose administration for peripheral blood stem cell mobilization. Pharmacotherapy 21(10): 1289
Medeiros, M.; Perez Urizar, J.; Mejia, N.; Ramirez, E.; Castaneda Hernandez, G.; Munoz, R. 2001: Pharmacokinetics of cyclosporin in children with steroid resistant nephrotic syndrome during relapse and remission states. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 229A
Medeiros, M.; Perez Urizar, J.; Pedraza Chaverri, J.; Castaneda Hernandez, G.; Munoz, R. 2001: Pharmacokinetics of cyclosporin in rats with experimental nephrotic syndrome. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 685A
Latteri, M.; Angeloni, G.; Silveri, N.G.; Manna, R.; Gasbarrini, G.; Navarra, P. 2001: Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. Clinical Pharmacokinetics 40(6): 473-483
Fawcett, L.B.; Beckman, D.A.; Sherrell, L.K.; Assadi, F.K. 2000: Pharmacokinetics of cysteamine in the pregnant rat and postnatal effects on offspring. Pediatric Research 47(4 Part 2): 81A
Savchenko, V.G.; Parovitchnikova, E.N.; Garmaeva, T.Z.; Skorokhod, A.A.; Isaev, V.G.; Vetvitsky, V.M.; Attaulakhanov, F.I.; Pivnik, A.V. 1999: Pharmacokinetics of daunorubicin entrapped in liposomes or erythrocytes -phase II study in refractory acute leukemias. Annals of Hematology 78(Suppl 2): S35
Nangia, A.; Cullen, E.; Niecestro, R.; Friedhoff, L. 2003: Pharmacokinetics of delayed-release valproate in healthy human subjects. Journal of Clinical Pharmacology 43(9): 1032
Cambus, J.P.; Saivin, S.; Thalamas, C.; Gianese, F.; Boneu, B.; Houin, G. 2000: Pharmacokinetics of dermatan sulfate in human volunteers. Haemostasis 30(1-2): 52-53
Mccrea, J.; Majumdar, A.; Busillo, J.; Panebianco, D.; Goldberg, M.R.; Murphy, G.; Gottesdiener, K.; Hesney, M.; Lates, C.; Blum, R. 2003: Pharmacokinetics of dexamethasone when given with aprepitant. Clinical Pharmacology and Therapeutics 73(2): P5
Cunningham, F.E.; Baughman, V.L.; Tonkovich, L.; Lam, N.; Layden, T. 1999: Pharmacokinetics of dexmedetomidine in patients with hepatic failure. Clinical Pharmacology and Therapeutics 65(2): 128
Palaparthy, R.; Kastrissios, H.; Sen, A.; Gulati, A. 1999: Pharmacokinetics of diaspirin crosslinked hemoglobin in a rat model of hepatic cirrhosis. FASEB Journal 13(5 Part 2): A810
Christian, M.S.; York, R.G.; Fisher, L.C. 2001: Pharmacokinetics of dibromoacetic acid administered to rats in drinking water during a range-finding reproduction study. Teratology 63(6): 278
Zimmermann, H.; Duvauchelle, T.; Gualano, V.; Kaufmann, G.; Bervoas Martin, S.; Breitbarth, H.; Mathieu, M.; Mellinger, U.; Ntsikoussalabongui, B.; Oettel, M.; Thebault, J.J. 1999: Pharmacokinetics of dienogest as a single drug or in combination with estradiol valerate or ethinylestradiol. Drugs of Today 35(Suppl C): 27-39
Mueller, H.J.; Ahlke, E.; Schrappe, M.; Boos, J. 1999: Pharmacokinetics of different asparaginases. Annals of Hematology 78(Suppl 2): S20
Giessmann, T.; Zschiesche, M.; Franke, G.; Gramatte, T.; Siegmund, W. 2002: Pharmacokinetics of different oral doses of propiverine. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R110
Rampal, S.; Chaudhary, R.K. 2000: Pharmacokinetics of diminazene in crossbred calves following single intramuscular administration. Indian Journal of Animal Sciences 70(7): 703-704
Recalenda, V.; Tagini, V.; Infante, L.; Buffa, E.; Novello, S.; Airoldi, M.; Bumma, C.; Cattel, L. 2000: Pharmacokinetics of docetaxel , carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck. Tumori 86(4 Suppl 1): 87-88
Shirazi, F.H.; Lotfalahi, A.; Rouini, M.; Stewart, D.J.; Tomiak, E.; Goel, R. 2000: Pharmacokinetics of docetaxel in patients given immediately before etoposide. Proceedings of the American Association for Cancer Research 41: 608
Reyes, J.F.; Preskorn, S.; Khan, A.; Kumar, D.; Cullen, E.; Pratt, R. 2001: Pharmacokinetics of donepezil and risperidone in males with schizophrenia. Clinical Pharmacology and Therapeutics 69(2): P44
Anonymous 2000: Pharmacokinetics of doxazosin gastrointestinal therapeutic system versus standard Potential benefits in hypertension. Journal of Hypertension 18(Suppl 4): S157
Lowe, E.S.; Balis, F.M.; Cole, D.E.; Goodspeed, W.; Drbohlav, N.; Wilson, W.H. 2002: Pharmacokinetics of doxorubicin and doxorubicinol in dose-adjusted EPOCH infusional chemotherapy. Proceedings of the American Association for Cancer Research 43: 429-430
Kumagai, Y.ji 2001: Pharmacokinetics of drugs and biological rhythm. Japanese Journal of Pharmacology 85(Suppl 1): 57P
Rosing, H.; Cvitkovic, E.; Jimeno, J.M.; Hillebrand, M.J.X.; Twelves, C.; Villalona, M.; Beijnen, J.H. 1999: Pharmacokinetics of ecteinscidin-743 in three different phase I trials. Proceedings of the American Association for Cancer Research 40: 82
Glover, K.A.; Samuelsen, O.B.; Skilbrei, O.T.; Boxaspen, K.; Lunestad, B.T. 2010: Pharmacokinetics of emamectin benzoate administered to Atlantic salmon, Salmo salar L., by intra-peritoneal injection. Journal of Fish Diseases 33(2): 183-186
Rippley, R.; Shahinfar, S.; Hogg, R.; Sakarcan, A.; Delucchi, A.; Blowey, D.; Walson, P.; Vogt, B.; Murphy, G.; Lo, M.; Hand, E.; Shaw, W.; Wells, T. 2000: Pharmacokinetics of enalapril in hypertensive children and infants. American Journal of Hypertension 13(4 Part 2): 126A
Cao, G.; Song, Y. 2002: Pharmacokinetics of enantiomers of a new antidiabetic agent in healthy subjects and its metabolism using isolated rats hepatocytes. Clinical Pharmacology and Therapeutics 71(2): P100
Gonzalez, C.; Moreno, L.; Fumuso, E.; Alvarez, G.; Bruno, S.; Alvarez, L.; Sanchez, S. 2003: Pharmacokinetics of enrofloxacin after intravenous and intrauterine administrations to mares with endometritis. Biocell 27(3): 390
Boothe, D.M.; Boeckh, A.; Wilkie, S.; Jones, S.A. 2000: Pharmacokinetics of enrofloxacin and its active metabolite, ciprofloxacin, following oral administration of 75, 10 and 20 mg/kg. Journal of Veterinary Internal Medicine 14(3): 354
Haines, G.R.; Brown, M.P.; Gronwall, R.R.; Merritt, K.A. 2000: Pharmacokinetics of enrofloxacin and orbifloxacin in mares. Veterinary Surgery 29(5): 464
Yun, H.I.; Park, B.K.; Lim, J.H.; Hwang, Y.H.; Park, S.C. 2003: Pharmacokinetics of enrofloxacin in the Crucian carp in freshwater. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 97-98
Seguin, M.A.; Papich, M.G.; Levy, J.K. 2001: Pharmacokinetics of enrofloxacin, a fluoroquinolone antibiotic, in neonatal kittens. Journal of Veterinary Internal Medicine 15(3): 319
King, J.R.; Nachman, S.; Yogev, R.; Aldrovandi, G.; Damle, B.; Hodge, J.; Wiznia, A.; Acosta, E.P. 2001: Pharmacokinetics of enteric-coated didanosine in HIV-infected pediatric patients. Pharmacotherapy 21(10): 1272
Kaplan, B.; Meier Kriesche, H.U.; Minnick, P.; Bastien, M.C.; Sechaud, R.; Yeh, C.M.; Balez, S.; Picard, F.; Schmouder, R. 2003: Pharmacokinetics of enteric-coated mycophenolate sodium in stable renal transplant patients with Neoral or Tacrolimus. Journal of the American Society of Nephrology 14(Abstracts Issue): 910A
Schueller, J.J.S.; Czejka, M.M.C.; Eder, I.I.E.; Niedermayr, A.A.N.; Ostermann, E.E.O. 2001: Pharmacokinetics of epirubicin and docetaxel in combination with herceptin in breast cancer patients. Breast Cancer Research and Treatment 69(3): 302
Mader, R.M.; Rizovski, B.; Wenzel, C.; Bartsch, R.; Zielinski, C.C.; Steger, G.G. 2003: Pharmacokinetics of epirubicin and paclitaxel during weekly administration in patients with metastasised breast cancer. EJC Suppls 1(5): S170-S171
Loadman, P.M.; Bibby, M.C.; Swaine, D.J.; Bradley, C.; Dent, J.; Perren, T.J. 2000: Pharmacokinetics of epirubicin in a phase II study of taxotere in combination with epirubicin and fluorouracil in patients with recurrent or metastatic breast cancer A Yorkshire collaborative breast cancer study. Proceedings of the American Association for Cancer Research 41: 607
Reid, S.E.; Tolbert, D.S.; Ferry, J.; Krause, S. 2003: Pharmacokinetics of eplerenone coadministered with glyburide and its effect on glyburide pharmacodynamics. Pharmacotherapy 23(10): 1328-1329
Tolbert, D.S.; Reid, S.E.; Roniker, B. 2002: Pharmacokinetics of eplerenone coadministered with other medications. Pharmacotherapy 22(10): 1331
Tolbert, D.S.; Reid, S.E.; Roniker, B. 2002: Pharmacokinetics of eplerenone in special populations. Pharmacotherapy 22(10): 1332
Holland, S.D.; Majumdar, A.; Musson, D.; Swan, S.; Sica, D.; Deutsch, P.; Xi, L.; Mistry, G.C.; Birk, K. 2001: Pharmacokinetics of ertapenem in renal insufficiency. Clinical Pharmacology and Therapeutics 69(2): P16
Boni, J.; Korth Bradley, J.; Punt, C.J.A.; Hanauske, A.; Weigang Koehler, K.; Thielert, C.; Frisch, J. 2001: Pharmacokinetics of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. European Journal of Cancer 37(Suppl 6): S68
Hasselgren, G.; Hassan Alin, M.; Andersson, T.; Claar Nilsson, C.; Nilsson, L.G.; Rohss, K. 2000: Pharmacokinetics of esomeprazole are not affected by age An assessment in the elderly. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1245
Sjovall, H.; Hagman, I.; Holmberg, J.; Rohss, K.; Hassan Alin, M. 2000: Pharmacokinetics of esomeprazole in patients with liver cirrhosis. Gastroenterology 118(4 Suppl 2 Pt 1): A21
Zhou, H.; Zitnik, R. 2004: Pharmacokinetics of etanercept are unaltered by concurrent administration of methotrexate in rheumatoid arthritis patients. Journal of Investigative Dermatology 122(3): A53
Zhou, H.; Buckwalter, M.; Boni, J.; Mayer, P.; Raible, D.; Wajdula, J.; Fatenejad, S.; Sanda, M. 2003: Pharmacokinetics of etanercept in ankylosing spondylitis patients A population-based investigation. Journal of Clinical Pharmacology 43(9): 1033
Nestorov, I.; Devries, T.; Zitnik, R. 2004: Pharmacokinetics of etanercept in patients with psoriasis. Journal of Investigative Dermatology 122(3): A55
Nestorov, I.; Zitnik, R. 2004: Pharmacokinetics of etanercept in patients with psoriasis after long term intermittent or continuous treatment. Journal of Investigative Dermatology 122(3): A56
Timmer, C.J.; Mulders, T.M. 2000: Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clinical Pharmacokinetics 39(3): 233-242
Reif, S.; Grimm, J.; Kingreen, D.; Siegert, W.; Schunack, W.; Jaehde, U. 2000: Pharmacokinetics of etoposide following administration of high-dose etoposide and etoposide phosphate. International Journal of Clinical Pharmacology and Therapeutics 38(3): 156-157
Morikawa, N.; Mori, T.; Kawashima, H.; Takeyama, M.; Hori, S. 1999: Pharmacokinetics of etoposide in plasma and cerebrospinal fluid in the space left by tumor removal. Annals of PharmacoTherapy 33(1): 115-116
Reyderman, L.; Kosoglou, T.; Statkevich, P.; Pember, L.; Maxwell, S.; Batra, V. 2002: Pharmacokinetics of ezetimibe in subjects with normal renal function or severe chronic renal insufficiency. Clinical Pharmacology and Therapeutics 71(2): P27
Maples, H.; James, L.; Stowe, C.; Chesney, R.; Christensen, M.; Blumer, J.; Wilson, J.; Wells, T.; Kearns, G. 2002: Pharmacokinetics of famotidine in children and adolescents with chronic renal failure. Clinical Pharmacology and Therapeutics 71(2): P4
Laroia, N.; Mcbride, M.C.; Guillet, R. 2000: Pharmacokinetics of felbamate in infants with hypoxic ischemic encephalopathy. Pediatric Research 47(4 Part 2): 461A
Jiang, H.X.; Fung, K.F.; Zeng, Z.L.; Chen, Z.L. 2003: Pharmacokinetics of florfenicol in pigs after different administrating routes. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 96
Switala, M.; Okoniewski, P.; Smutkiewicz, A.; Jaworski, K. 2003: Pharmacokinetics of florfenicol in turkeys. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 116-117
Davis, G.A.; Rapp, R.P.; Kearney, P.A.; Ensom, M.H. 2001: Pharmacokinetics of fluconazole in trauma patients with postpyloric feeding tubes. Annals of PharmacoTherapy 35(11): 1492-1494
Peggins, J.O.; Idowu, O.R.; Deveau, I.; Marino, M.T.; Von Bredow, J.D.; Thomas, M.H. 2002: Pharmacokinetics of four different drugs in beef steers and lactating dairy cows. Abstracts of Papers American Chemical Society 224(1-2): AGRO 9
Gogoi, T.; Khanikor, H.N.; Lahon, L.C. 2001: Pharmacokinetics of furazolidone in local goats of Assam. Indian Veterinary Medical Journal 25(2): 181-182
Zhang, X.; Keith, N.; Rodwell, A.; Lang, J.; Rouzier, R.; Dorr, A.; Kolis, S.; Stiles, M.; Kinchelo, T.; Patel, I. 2002: Pharmacokinetics of fusion inhibitor T-20 in HIV-1 infected patients. Clinical Pharmacology and Therapeutics 71(2): P27
Ohman, I.; Vitols, S.; Tomson, T. 2003: Pharmacokinetics of gabapentin in neonates and during lactation. Tulunay, F C, Orme, M European collaboration: Towards drug development and rational drug therapy: 169
Zhao, Q.; Zhou, H.; Huang, F. 2002: Pharmacokinetics of galantamine and risperidone administered alone and in combination in healthy elderly subjects. Clinical Pharmacology and Therapeutics 71(2): P97
Scholle, C.; Czock, D.; Zellner, D.; Kwan, J.; Brown, F.; Banken, L.; Keller, F. 2000: Pharmacokinetics of ganciclovir after prodrug valganciclovir in renal impairment. Kidney and Blood Pressure Research 23(3-5): 333
Ohman, I.; Vitols, S.; Tomson, T. 2003: Pharmacokinetics of gapapentin in neonates and during lactation. Tulunay, F C, Orme, M European collaboration: Towards drug development and rational drug therapy: 140
Noveck, R.J.; Vargas, R.; Russo, R.; Bello, A.; Gajjar, D.; Grasela, D. 2003: Pharmacokinetics of garenoxacin in healthy subjects and in subjects with hepatic impairment. Clinical Pharmacology and Therapeutics 73(2): P79
Lubasch, A.; Keller, I.; Borner, K.; Koeppe, P.; Lode, H. 2001: Pharmacokinetics of gatifloxacin in comparison to five other fluoroquinolones after single oral administration in healthy volunteers. Journal of Antimicrobial ChemoTherapy 47(Suppl S1): 38-39
Nix, D.; Ryan, D.P.; Eder, J.P.; Fidias, P.; Guerciolini, R.; Sao, N.; Supko, J. 2003: Pharmacokinetics of gemcitabine and the proteasome inhibitor bortezomib in adult patients with solid malignancies. Proceedings of the American Association for Cancer Research 44: 1061-1062
Upmeier, A.; Elswick, B.A.; Parkinson, H.D.; Krol, W.L.; Borghoff, S.J. 2003: Pharmacokinetics of genistein following intravenous and oral administration to adult female Sprague-Dawley rats. Toxicological Sciences 72(S-1): 146-147
Trenk, D.; Hajda, J.; Stengele, E.; Jaehnchen, E. 2002: Pharmacokinetics of glycerol trinitrate and its metabolites after topical peri-anal administration of different glycerol trinitrate-containing ointments. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R110
Marino, G.; Rustgi, V.K.; Flockard, D.; Kuo, P.C.; Plotkin, J.S.; Johnson, L.B.; Islam, K. 2000: Pharmacokinetics of hepapoietin in patients with chronic liver disease. Gastroenterology 118(4 Suppl 2 Pt 2): AASLD A146
Ghahramani, P.; Barton, C.; Leyland Jones, B. 2003: Pharmacokinetics of herceptin administered three-weekly compared to weekly A simulation based on data from the clinical studies. Breast 12(Suppl 1): S40
Nava Ocampo, A.A.; Koren, G.; Pastrak, A.; Cruz, T. 2004: Pharmacokinetics of high doses of cyanocobalamin administered by IV injection in healthy volunteers. Clinical Pharmacology and Therapeutics 75(2): P84
Eder, G.; Fritsch, S.; Dauber, E.; Neumueller, J.; Mayr, W.R. 2000: Pharmacokinetics of human rhesus immunglobulin. Vox Sanguinis 78(Suppl 1): P197
Bauer, R.J.; Ruan, H.; Chen, Z.; Vanhove, G.F.A.; Fourney, P.; Ammons, W.S.eve 2002: Pharmacokinetics of human-engineered ING-1 in rats and cynomolgus monkeys. Proceedings of the American Association for Cancer Research 43: 428
Arnold, J.D.; Rajan, V.S.; Gross, A.; Veldhuis, J.D.; Leslie, G.; Milmlow, D.; Silink, M. 1999: Pharmacokinetics of hydrocortisone in extremely premature infants in the first six weeks of life. Pediatric Research 45(4 Part 2): 183A
Coulet, M.N.G.; Morello, C.; Oudeyer, V.; Cox, P.G.F. 2003: Pharmacokinetics of ibafloxacin following oral administration to healthy cats. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 119
Han, E.E.; Beringer, P.M.; Louie, S.G.; Gill, M.A.; Shapiro, B.J. 2004: Pharmacokinetics of Ibuprofen in children with cystic fibrosis. Clinical Pharmacokinetics 43(3): 145-156
Moberly, J.B.; Mujais, S.; Gehr, T.; Hamburger, R.; Sprague, S.; Kucharski, A.; Reynolds, R.; Ogrinc, F.; Martis, L.; Wolfson, M. 2002: Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney International. Suppl 81: S23-S33
Brain, E.G.; Sauvage, N.; Gauzan, M.F.; Weill, S.; Goupil, A.; Santoni, J.; Lokiec, F. 2000: Pharmacokinetics of ifosfamide and its main metabolites following continuous infusion and 3H-infusion Preliminary data from a randomized trial with intrapatient cross-over. Proceedings of the American Association for Cancer Research 41: 606
Tran, J.Q.; Petersen, C.; Garrett, M.; Schultz Smith, M.; Escobar, J.; Lillibridge, J.H.; Kerr, B.M. 2000: Pharmacokinetics of indinavir/delavirdine 1200/600 mg twice daily with and without food. AIDS 14(Suppl 4): S92
Boyd, M.A.; Aarnoutse, R.E.; Ruxrungtham, K.; Stek, M.J.; Van Heeswijk, R.P.G.; Lange, J.M.A.; Cooper, D.A.; Phanuphak, P.; Burger, D.M. 2003: Pharmacokinetics of indinavir/ritonavir in combination with efavirenz in HIV-1-infected subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes 34(2): 134-139
Gagliardi, L.; Bray, M.; Fumagalli, M.; Stucchi, I.; Pugni, L.; Mosca, F. 2001: Pharmacokinetics of indocyanine green in preterm infants. Pediatric Research 49(2): 276
Engelke, K.J.; Townsend, R.W.; Mulshine, J.L.; Deluca, L.M.; Placke, M.E.; Imondi, A.R.; Dahl, A.R. 2000: Pharmacokinetics of inhaled 13-cis retinoic acid in beagle dogs. Proceedings of the American Association for Cancer Research 41: 54
Miller, J.; Zumbrunnen, T.; Brennan, J.J. 2003: Pharmacokinetics of inhaled dronabinol. Journal of Clinical Pharmacology 43(9): 1039
Plum, A.; Andersen, L.; Agerso, H. 1999: Pharmacokinetics of insulin aspart, a short acting insulin analogue in rats and dogs. Diabetes 48(Suppl 1): A451
Jacobsen, L.V.; Popescu, G.; Plum, A. 2002: Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia 45(Suppl 2): A 259-A 260
Danne, T.; Luepke, K.; Walte, K.; Von Schuetz, W.; Gall, M.A.ne 2003: Pharmacokinetics of insulin detemir is similar in children, adolescents and adults with type 1 diabetes. Diabetes 52(Suppl 1): A116
Melendez, O.; Calvanelli, B.L.; Foote, E.F.; Dahl, N.V.; Sherman, R.A.; Kapoian, T. 2000: Pharmacokinetics of intermittent cefazolin during continuous cycling peritoneal dialysis. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 213A
Booranalertpaisarn, V.; Eiam Ong, S.; Praditpornsilpa, K.; Chusil, S.; Tungsanga, K. 2002: Pharmacokinetics of intermittent intraperitoneal ceftazidime in the empirical therapy of dialysis-related peritonitis in continuous ambulatory peritoneal dialysis patients. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 384A-385A
Lindegaard, C.; Frost, A.B.; Thomsen, M.H.; Larsen, C.; Hansen, S.H.é; Andersen, P.H. 2010: Pharmacokinetics of intra-articular morphine in horses with lipopolysaccharide-induced synovitis. Veterinary Anaesthesia and Analgesia 37(2): 186-195
Shirbacheh, M.; Jones, J.; Harralson, T.; Edelstein, J.; Tecimer, T.; Breidenbach, W.; Jevans, A.; Maldonado, C.; Barker, J.; Gruber, S. 1999: Pharmacokinetics of intraaterial tacrolimus delivery to the rabbit forelimb. FASEB Journal 13(4 Part 1): A150
Wermeling, D.P.; Rudy, A.C.; Archer, S.M.; Rayens, M.K.; Jay, M. 2000: Pharmacokinetics of intranasal hydromorphone in healthy subjects. Pharmacotherapy 20(10): 1263
Kokki, H.; Karvinen, M.; Suhonen, P. 2003: Pharmacokinetics of intravenous and rectal ketoprofen in young children. Clinical Pharmacokinetics 42(4): 373-379
Landoni, M.F.; Albarellos, G.A.; Montoya, L.; Hallu, R.E. 2003: Pharmacokinetics of intravenous and two intramuscular formulations of amoxicillin in cats. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 135-136
Rodman, J.H.; Stricklin, L.M.; Horwitz, E.M.; Cunningham, J.M.; Heideman, R.L.; Call, S.K.; Bowman, L.C. 2001: Pharmacokinetics of intravenous busulfan in pediatric patients. Clinical Pharmacology and Therapeutics 69(2): P81
Kerr, J.Z.; Berg, S.L.; Egorin, J.J.; Dauser, R.; Nuchtern, J.; Durfee, J.; Mcguffey, L.; Aleksic, A.; Blaney, S.M. 2000: Pharmacokinetics of intravenous gemcitabine in nonhuman primates. Proceedings of the American Association for Cancer Research 41: 706
Tantimongkolsuk, C.; Arkachaisri, T.; Visitsunthorn, N.; Wongkajornsilp, A.; Vichyanond, P. 2003: Pharmacokinetics of intravenous immunoglobulin administered via subcutaneous route in patients with hypogammaglobulinemia. Journal of Allergy and Clinical Immunology 111(2 Abstract Suppl): S227
Ensom, M.H.H.; Houlihan, E.; Kwan, L.; Li, J.; Stephenson, M.D. 2002: Pharmacokinetics of intravenous immunoglobulin in females with the antiphospholipid antibody syndrome. Pharmacotherapy 22(10): 1372
Ensom, M.H.H.; Amos, C.; Pi, D.; Schellenberg, R.R.bert 2001: Pharmacokinetics of intravenous immunoglobulin in patients with hypogammaglobulinemia. Pharmacotherapy 21(10): 1290-1291
Ensom, M.H.H.; Lai, A.; Houlihan, E.; Stephenson, M.D. 2003: Pharmacokinetics of intravenous immunoglobulin in pregnancy. Pharmacotherapy 23(10): 1367
D.W.ldt, S.N.; Murry, D.J.; Kearns, G.L.; Hop, W.C.; Abdel Rahman, S.; Van Den Anker, J.N. 2001: Pharmacokinetics of intravenous midazolam and 1-OH-midazolam in preterm infants. Pediatric Research 49(4 Part 2): 454A
Charmandari, E.; Hindmarsh, P.C.; Johnston, A.; Brook, C.G.D. 2000: Pharmacokinetics of intravenously administered hydrocortisone in patients with adequately controlled congenital adrenal hyperplasia. Hormone Research 53(Suppl 2): 71
Vriesema, J.; Schalken, J.; Witjes, F. 2002: Pharmacokinetics of intravesical gemcitabine A preclinical study in pigs. European Urology Suppls 1(1): 123
Zheng, J.H.; Knemeyer, I.; Au, J.L.S.; Coyle, J.D.; Wientjes, M.G. 2000: Pharmacokinetics of intravesical mitomycin C in a phase III trial Population-based analysis versus conventional analysis. Proceedings of the American Association for Cancer Research 41: 607
Lokiec, F.; Alexandre, J.; Raymond, E.; Brain, E.; Kaci, M.O.; Lagree, S.; Vignot, S.; Smith, S.; Cvitkovic, E.; Misset, J.L. 2001: Pharmacokinetics of irofulven using three different intermittent 5-minutes infusion dosing schedules in advanced solid tumors Final results. European Journal of Cancer 37(Suppl 6): S66-S67
Lokiec, F.; Raymond, E.; Alexandre, J.; Brain, E.; Kaci, M.O.; Lagree, S.; Smith, S.; Vanderbilt, K.; Cvitkovic, E.; Misset, J.L. 2001: Pharmacokinetics of irofulven using two different intermittent dosing schedules as a 30 minute infusion in advanced solid tumors Preliminary data. European Journal of Cancer 37(Suppl 6): S68
Roy, V.; Gupta, D.; Gupta, P.; Sethi, G.R.; Mishra, T.K. 2010: Pharmacokinetics of isoniazid in moderately malnourished children with tuberculosis. International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 14(3): 374-376
Raleigh, S.M.; Verschoyle, R.D.; Bowskill, C.; Steele, F.; Silvester, J.; Pastorino, U.; Staniforth, J.; Lim, C.K.; Gescher, A. 1999: Pharmacokinetics of isotretinoin in rats following oral dosing or aerosol inhalation. British Journal of Cancer 80(Suppl 2): 96
Lee, U.; Choi, Y.H.; Kim, S.H.; Lee, B.K. 2010: Pharmacokinetics of itraconazole in diabetic rats. Antimicrobial Agents and ChemoTherapy 54(2): 931-933
Santos, Y.; Ballesteros, C.; Ros, J.M.; Diaz, D.C.; Rodriguez, C.; Encinas, T. 2000: Pharmacokinetics of ketorolac enantiomers in sheep after intramuscular administration of the racemate. Methods and Findings in Experimental and Clinical Pharmacology 22(6): 511
Gunasekaran, T.; Pan, W.J.; Torres Pinedo, R.; Book, L.; Gremse, D.; Steffen, R.; Czinn, S.; Chiu, Y.L.; Pilmer, B.L.; Fitzgerald, J. 2000: Pharmacokinetics of lansoprazole in adolescent patients with gastroesophageal reflux disease. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1241
Gunasekaran, T.; Pan, W.J.; Torres Pinedo, R.; Book, L.; Gremse, D.; Steffen, R.; Chiu, Y.; Keith, R.; Fitzgerald, J. 2000: Pharmacokinetics of lansoprazole in adolescents with GERD. JPGN 31(Suppl 2): S97
Patsalos, P.N. 2000: Pharmacokinetics of levetiracetam Towards ideal characteristics. European Journal of Neurology 7(Suppl 3): 178-179
Bellman, R.; Egger, P.; Dunzendorfer, S.; Gritsch, W.; Bellmann Weiler, R.; Joannidis, M.; Wiedermann, C.J. 2000: Pharmacokinetics of levofloxacin in critically ill patients undergoing continuous veno-venous hemofiltration. Journal of Clinical Pharmacology 40(9): 1059
Hendershot, P.E.; Jungbluth, G.L.; Cammarata, S.K.; Hopkins, N.K. 1999: Pharmacokinetics of linezolid in patients with liver disease. Journal of Antimicrobial ChemoTherapy 44(Suppl A): 55
Mazoit, J.-X.; Dalens, B.J. 2004: Pharmacokinetics of local anaesthetics in infants and children. Clinical Pharmacokinetics 43(1): 17-32
Zhu, Y.; Statkevich, P.; Cutler, D.L.; Calzetta, A.; Curtis, D.; Batra, V.K. 2004: Pharmacokinetics of lonafarnib , a farnesyl protein transferase inhibitor. Clinical Pharmacology and Therapeutics 75(2): P59
Chen, D.; Yeh, T.; Song, S.; Au, J.L.; Villalona Calero, M.; Otterson, G.; Kanter, S.; Chan, K.; Wientjes, M.G. 2002: Pharmacokinetics of low dose suramin in combination with paclitaxel and carboplatin in non-small cell lung cancer patients. Proceedings of the American Association for Cancer Research 43: 551
Ensom, M.H.H.; Ballem, P.J.; Chong, G.; Stephenson, M.D. 2000: Pharmacokinetics of low molecular weight heparin and unfractionated heparin in females with antiphospholipid antibody syndrome. Pharmacotherapy 20(10): 1272
Ensom, M.H.H.; Stephenson, M.D. 2004: Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. Journal of the Society for Gynecologic Investigation 11(6): 377-383
Fareed, J.; Fu, K.; Yang, L.H.; Hoppensteadt, D.A. 1999: Pharmacokinetics of low molecular weight heparins in animal models. Seminars in Thrombosis and Hemostasis 25(Suppl 3): 51-55
Hempel, G.; Ruebe, C.; Mosler, C.; Lehmkuhl, D.; Wienstroer, M.; Wagner, A.; Schuck, A.; Willich, N.; Boos, J. 2000: Pharmacokinetics of low-dose paclitaxel in patients with brain tumors. International Journal of Clinical Pharmacology and Therapeutics 38(3): 158-159
Scott, G.; Rordorf, C.; Reynolds, C.; Kalbag, J.; Looby, M.; Milosavljev, S.; Weaver, M.; Huff, J.P.; Ruff, D.A. 2004: Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clinical Pharmacokinetics 43(7): 467-478
Reynolds, C.; Scott, G.; Looby, M.; Milosavljev, S.; Huff, J.P.; Ruff, D.A.; Rordorf, C. 2003: Pharmacokinetics of lumiracoxib in synovial fluid and plasma of patients with rheumatoid arthritis. Tulunay, F C, Orme, M European collaboration: Towards drug development and rational drug therapy: 123
Debruyne, D.; Sobrio, F.; Hinschberger, A.; Coquerel, A.; Barre, L. 2000: Pharmacokinetics of mecamylamine, a potential radioligand for nicotinic receptor. Fundamental and Clinical Pharmacology 14(3): 251
Cullberg, M.; Eriksson, H.; Eriksson, U.G.; Frison, L.; Karlsson, M.O.; Schulman, S.; Thuresson, A.; Wahlander, K. 2002: Pharmacokinetics of melagatran after oral dosing with ximelagatran, a direct thrombin inhibitor, in patients with acute venous thromboembolism. Clinical Pharmacology and Therapeutics 71(2): P61
Eriksson, U.G.; Mandema, J.W.; Karlsson, M.O.; Frison, L.; Gisleskog, P.O.; Wählby, U.; Hamrén, B.; Gustafsson, D.; Eriksson, B.I. 2003: Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clinical Pharmacokinetics 42(7): 687-701
Eriksson, U.G.; Johansson, L.; Frison, L.; Gustafsson, D.; Mandema, J.; Karlsson, M.O.; Eriksson, D.; Fager, G. 2001: Pharmacokinetics of melagatran in young and elderly healthy subjects and orthopedic surgery patients. Clinical Pharmacology and Therapeutics 69(2): P24
Cullberg, M.; Clason, S.M.; Eriksson, H.; Karlsson, M.O.; Lundstrom, T.; Nystrom, P.; Schulman, S.; Wahlander, K. 2003: Pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and the relationship to clinical response in extended secondary prevention of venous thromboembolism. Tulunay, F C, Orme, M European collaboration: Towards drug development and rational drug therapy: 125
Eriksson, U.G.; Johansson, L.; Frison, L.; Fager, G. 2001: Pharmacokinetics of melagratran after oral dosing with H 376/95 in healthy male subjects of different ethnic origin. Clinical Pharmacology and Therapeutics 69(2): P24
Buffa, E.; Novello, S.; Passera, R.; Infante, L.; De Simone, M.; Cattel, L. 2000: Pharmacokinetics of melphalan in hyperthermic perfusion of isolated limb. Tumori 86(4 Suppl 1): 82
Hickstein, H.; Peszynska, A.; Freytag, J.; Schulz, M.; Henschel, J.; Adam, U.; Pertschy, A.; Francke, A.; Ehmcke, H.; Riethling, A.K.; Drewelow, B.; Schmidt, R. 1999: Pharmacokinetics of meropenem in patients with acute renal failure treated by continous veno-venous hemodialysis. Nephrology Dialysis Transplantation 14(9): A71
Thalhammer, F.; Hörl, W.H. 2000: Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clinical Pharmacokinetics 39(4): 271-279
Blust, R.; Chowdhury, M.J. 2000: Pharmacokinetics of metal uptake and elimination in aquatic organisms. Comparative Biochemistry and Physiology Part A Molecular and Integrative Physiology 126A(Suppl 1): S14
Gao, X.; Christensen, M.; Burghen, G.A.; Velasquez Mieyer, P.; Moore, K.T.; Donahue, S.R.; Reeves, R.A.; Turner, K.C. 2003: Pharmacokinetics of metformin in pediatric type 2 diabetic and healthy adult subjects. Clinical Pharmacology and Therapeutics 73(2): P46
Calvo, R.; Lukas, J.C.; Rodriguez, M.; Carlos, M.A.; Suarez, E. 2002: Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz. British Journal of Clinical Pharmacology 53(2): 212-214
Ho, T.; Selby, P.; Kapur, B.; Phil, D.; Ito, S. 2001: Pharmacokinetics of methadone in breast milk. Clinical Pharmacology and Therapeutics 69(2): P51
Thompson, P.; Dreyer, Z.E.; Blaney, S.; Berg, S.; Murry, D.; Bomgaars, L. 2004: Pharmacokinetics of methotrexate in infants with acute lymphoblastic leukemia. Clinical Pharmacology and Therapeutics 75(2): P47
Markowitz, J.S.; Straughn, A.B.; Patrick, K.S.; DeVane, C.L.; Pestreich, L.; Lee, J.; Wang, Y.; Muniz, R. 2003: Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clinical Pharmacokinetics 42(4): 393-401
Okano, Y.; Osaka, R.; Shinozaki, H.; Ishida, S.; Yamakawa, K.; Kato, M. 2004: Pharmacokinetics of midazolam and propofol in sedated state patients during hypothermia. Journal of Pharmacological Sciences 94(Suppl 1): 197P
Kang, W.; Jung, H.; Yoon, Y.; Liu, K.; Cha, I.; Shin, J. 2004: Pharmacokinetics of midazolam in Korean healthy subjects with CYP3A4 wild type and *18 variant. Clinical Pharmacology and Therapeutics 75(2): P67
Nordgreen, J.; Kolsrud, H.H.; Ranheim, B.; Horsberg, T.E. 2009: Pharmacokinetics of morphine after intramuscular injection in common goldfish Carassius auratus and Atlantic salmon Salmo salar. Diseases of Aquatic Organisms 88(1): 55-63
Hung, Y.P.; Fleckenstein, L.; Dzimianski, M.T.; Mccall, J.W. 1999: Pharmacokinetics of moxidectin in dogs with lymphatic infections of Brugia pahangi. American Journal of Tropical Medicine and Hygiene 61(3 Suppl): 441-442
Stass, H.; Lettieri, J. 1999: Pharmacokinetics of moxifloxacin in special populations. Drugs 58(Suppl 2): 233-234
Abrams, L.; Skee, D.; Natarajan, J.; Wong, F.; Lasseter, K.C. 2000: Pharmacokinetics of multiple cycles of a contraceptive patch. Journal of Clinical Pharmacology 40(9): 1047
Tandon, V.; Rajagopalan, P.; Cherstniakova, S.A.; Chiang, N.; Vocci, F.; Elkashef, A.; Mojsiak, J.; Haigney, M.; Cantilena, L.R. 2001: Pharmacokinetics of multiple escalating doses of GBR12909 in healthy volunteers. Clinical Pharmacology and Therapeutics 69(2): P61
Ensom, M.H.H.; Partovi, N.; Kwan, L.; Decarie, D.; Ignaszewski, A.P.; Fradet, G.; Levy, R.D. 2002: Pharmacokinetics of mycophenolate in the early period following lung and heart transplantation. Pharmacotherapy 22(10): 1371
Jenke, A.; Renner, U.; Mueller, M.; Guenther, H.; Helwig, A.; Freiberg Richter, J.; Platzbecker, U.; Plettig, R.; Bornhaeuser, M.; Ehninger, G. 2000: Pharmacokinetics of mycophenolate mofetil combined with cyclosporine A as graft versus host disease prophylaxis after blood stem cell transplantation Impact of conditioning therapy. Onkologie 23(Sonderheft 7): 120
Julasareekul, W.; Eiam Ong, S.; Sueblinwong, T.; Chusilp, S.; Tungsanga, K. 2001: Pharmacokinetics of mycophenolate mofetil in Thai kidney transplantation patients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 898A
Aigrain, E.J.; Shaghaghi, E.K.; Baudouin, V.; Popon, M.; Loirat, C. 2000: Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients. Transplantation Proceedings 32(2): 388-390
Haidinger, M.; Neumann, I.; Meisl, F.T. 2001: Pharmacokinetics of mycophenolate mofetil in renal recipients and pts with autoimmune diseases. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 103A
LiXiaoHong; XiongZhiLi; LuShan; ZhangYi; LiFaMei 2010: Pharmacokinetics of naringin and its metabolite naringenin in rats after oral administration of Rhizoma Drynariae extract assayed by UPLC-MS/MS. Chinese Journal Of Natural Medicines: 1, 40-46
Mirochnick, M.; Bryson, Y.; Stek, A.; Mofenson, L.; Connor, J.; Watts, H.; Huang, S.; Hughes, M.; Cunningham Schrader, B.; Purdue, L.; Asfaw, Y.; Smith, E. 2003: Pharmacokinetics of nelfinavir and its M8 metabolite in pregnant HIV-infected women and their infants PACTG 353. Pediatric Research 53(4 Part 2): 331A
Litalien, C.; Faye, A.; Compagnucci, A.; Jacqz Aigrain, E. 2001: Pharmacokinetics of nelfinavir and its active metabolite in very young infants infected with human immunodeficiency virus. Pediatric Research 49(4 Part 2): 454A
Izzedine, H.; Diquet, B.; Launay-Vacher, V.; Jouan, M.; Theou, N.; Deray, G. 1999: Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency. Aids 13(14): 1989
Chapelle, T.; Roeyen, G.; De Greef, K.; Verpooten, G.A.; Bosmans, J.L.; Martin, M.; De Broe, M.E.; Ysebaert, D.K. 2002: Pharmacokinetics of neoral before and after total gastrectomy in a renal transplant patient. Transplantation Proceedings 34(3): 805-806
Mirochnick, M.; Siminski, S.; Fenton, T.; Sullivan, J. 1999: Pharmacokinetics of nevirapine in infants following in utero exposure. Pediatric Research 45(4 Part 2): 168A
Villa, R.; Cagnardi, P.; Belloli, C.; Bacchetta, S.; Ferro, E.; Carli, S. 2003: Pharmacokinetics of nimesulide in the horse. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 107
Han, J.; Takeshita, K.; Utsumi, H. 2003: Pharmacokinetics of nitroxyl probe in mouse lung In vivo ESR study. Free Radical Biology and Medicine 35(Suppl 1): S118
Day, R.O.; McLachlan, A.J.; Graham, G.G.; Williams, K.M. 1999: Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clinical Pharmacokinetics 36(3): 191-210
Chun, H.; Shon, J.; Yoon, Y.; Kim, K.; Park, S.; Shin, J. 2002: Pharmacokinetics of ofloxacin in patients with multi-drug resistant tuberculosis. Clinical Pharmacology and Therapeutics 71(2): P85
Rani, S.; Cherian, B.; Nivsarkar, M.; Guttikar, M.; Zope, S.; Padh, H. 2001: Pharmacokinetics of olanzapine in Asian Indians and comparison with other populations Possibility of interethnic differences. Indian Journal of Pharmacology 33(4): 305-306
Sato, N.; Kobayashi, H.; Saga, T.; Togashi, K.; Konishi, J.; Fujibayashi, Y.; Brechbiel, M.W. 2001: Pharmacokinetics of oligo-DNA complexed with polyamidoamine dendrimers or dendrimer-avidin conjugates in intraperitoneal tumor model of mice. Proceedings of the American Association for Cancer Research 42: 31
Goddard, P.M.; Raynaud, F.; Nutley, B.; Fisher, P.; Lane, D.; Workman, P. 1999: Pharmacokinetics of olomoucine, a cyclin dependent kinase inhibitor, following IV administration to mice. British Journal of Cancer 80(Suppl 2): 92
Piqué, J.M.; Feu, F.; de Prada, G.; Röhss, K.; Hasselgren, G.ör. 2002: Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. Clinical Pharmacokinetics 41(12): 999-1004
Kumar, R.; Dixit, R.K.; Satpathi, D.; Garg, S.K.; Chawla, Y.K.; Bhargava, V.K. 2001: Pharmacokinetics of omeprazole in patients with cirrhosis and portal vein thrombosis. Indian Journal of Pharmacology 33(2): 136
Cambus, J.P.; Saivin, S.; Heilmann, J.J.; Caplain, H.; Boneu, B.; Houin, G. 2000: Pharmacokinetics of once daily 175 Ukg-1 of Tinzaparin for 5 days in human volunteers. Haemostasis 30(1-2): 53
Jones, M.D.; Armitstead, J.A.; Smith, K.M.; Evans, A.T.; Davis, G.A. 2003: Pharmacokinetics of once-daily aminoglycoside dosing in postpartum patients. Pharmacotherapy 23(10): 1345
Tegeder, I.; Lötsch, J.; Geisslinger, G. 1999: Pharmacokinetics of opioids in liver disease. Clinical Pharmacokinetics 37(1): 17-40
Cabarrocas, X.; Jansat, J.M.; Ferrer, P.; Luria, X. 2000: Pharmacokinetics of oral almotriptan during and outside a migraine attack. Cephalalgia 20(4): 417-418
Randinitis, E.J.; Brodfuehrer, J.; Vassos, A.B. 1999: Pharmacokinetics of oral and intravenous clinafloxacin. Drugs 58(Suppl 2): 252-253
Frgala, T.; Vlckova, J.; Sun, B.C.; Gupta, S.; Vishnuvajjala, B.R.; Maurer, B.J.; Reynolds, C.P. 2002: Pharmacokinetics of oral and intravenous formulations of N- -retinamide in nude mouse xenograft models. Proceedings of the American Association for Cancer Research 43: 276
Lal, J.; Kumar, V.; Gupta, R.C. 2003: Pharmacokinetics of oral and transdermal administration of a sulphur mustard decontaminant CC-2 urea in rats A preliminary study. Indian Journal of Pharmacology 35(5): 297-303
Schwahn, B.; Hafner, D.; Hohlfeld, T.; Laryea, M.D.; Wendel, U. 2000: Pharmacokinetics of oral betaine in healthy subjects. Journal of Inherited Metabolic Disease 23(Suppl 1): 66
Gendjar, S.R.; Moriyama, B.; Bailey, E.M.; Faber, M.; Shetty, A.; Borg, D.L.; Edwards, D. 2001: Pharmacokinetics of oral linezolid in patients on peritoneal dialysis. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 427A-428A
D.W.ldt, S.N.; Murry, D.J.; Kearns, G.L.; Hop, W.C.J.; Abdel Rahman, S.; Van Den Anker, J.N. 2001: Pharmacokinetics of oral midazolam and 1-OH-midazolam in preterm infants. Clinical Pharmacology and Therapeutics 69(2): P20
Johnson, T.N.; Rostami Hodjegan, A.; Chakrapani, A.; Tucker, G.T. 2001: Pharmacokinetics of oral midazolam in children. British Journal of Clinical Pharmacology 51(4): 365P
Thakur, P.A.; Dalvi, S.S.; Gogtay, N.G.; More, B.D.; Gupta, A.H.; Nandanwar, Y.S.; Kshirsagar, N.A. 2003: Pharmacokinetics of oral nevirapine suspension in HIV-1 infected pregnant mothers for prevention of vertical transmission in Mumbai. Indian Journal of Pharmacology 35(4): 277
Ferron, G.M.; James, L.P.; Kearns, G.L.; Blumer, J.; Abell, M.; Mako, B.; Mayer, P.R.; Getsy, J.; Paul, J. 2002: Pharmacokinetics of oral pantoprazole in pediatric patients. Pharmacotherapy 22(10): 1358
Colker, C.M.; Kalman, D.S.; Antonio, J. 1999: Pharmacokinetics of orally ingested 19-nor-4-androsten-3,17-diol and 19-nor-4-androsten-3,17-dione in healthy resistance trained adult males. FASEB Journal 13(5 Part 2): A1043
Mather, L.E.; Kam, P.C.; Morishige, R.J.; Otulana, B.A.; Dayton, F.; Rubsamen, R.M. 2000: Pharmacokinetics of orally inhaled fentanyl in healthy subjects. Journal of Clinical Pharmacology 40(9): 1060
Mangat, S.; Zheng, C.; Balez, S.; Nedelman, J.R. 2003: Pharmacokinetics of oxcarbazepine during adjunctive therapy in pediatric patients with inadequately controlled partial seizures. Epilepsia 44(Suppl 9): 102
Kokki, H.; Rasanen, I.; Reinikainen, M.; Suhonen, P.; Vanamo, K.; Ojanperä, I. 2004: Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clinical Pharmacokinetics 43(9): 613-622
Martinez, M.A.; Martinez Larranaga, M.R.; Lobo, M.G.; Diaz, M.J.; Garcia Uzcategui, Y.; Martinez, M.; Anadon, A. 2003: Pharmacokinetics of oxytetracycline after intravenous administration in pigs. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 114-115
Singh, M.; Varshneya, C.; Srivastava, A.K. 2003: Pharmacokinetics of oxytetracycline after intravenous administration in poultry. Indian Journal of Animal Sciences 73(5): 515-516
Zhai, S.; Weiser, T.S.; Nguyen, D.M.; Figg, W.D.; Schrump, D.S. 2000: Pharmacokinetics of paclitaxel administered via isolated lung perfusion in sheep. Proceedings of the American Association for Cancer Research 41: 325
Kirsch, R.E.; Hawarden, D.; Theron, I.; Venter, J.L.; Hartmann, M.; Luhmann, R.; Huber, R.; Wurst, W. 1999: Pharmacokinetics of pantoprazole in patients with liver insufficiency due to chronic hepatitis. Gastroenterology 116(4 Part 2): A216
Bruno, R.; Sacchi, P.; Ciappina, V.; Maffezzini, E.; Patruno, S.F.A.; Zocchetti, C.; Filice, G. 2003: Pharmacokinetics of peginterferon ALFA-2A compared to peginterferon ALFA-2B in naive patients with chronic hepatitis C. Journal of Hepatology 38(Suppl 2): 129-130
Gabizon, A.; Shmeeda, H.; Barenholz, Y. 2003: Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clinical Pharmacokinetics 42(5): 419-436
Kemper, R.A.; Jepson, G.W. 2003: Pharmacokinetics of perfluorooctanoic acid in male and female rats. Toxicological Sciences 72(S-1): 148
Woo, E.W.; Messmann, R.A.; Headlee, D.; Arbuck, S.G.; Murgo, A.J.; Sausville, E.A.; Figg, W.D. 2001: Pharmacokinetics of perifosine, an oral alkylphosphocholine signal transduction modulator, in a phase I trial with different loading and maintenance schedules in patients with refractory neoplasm. Proceedings of the American Association for Cancer Research 42: 534-535
Naile, T.; Cao, H.; Liang, W.; Mills, S.E. 1999: Pharmacokinetics of pig beta-Adrenergic receptors. Journal of Animal Science 77(Suppl 1): 160
Scott, G.; Osborne, S.A.; Greig, G.; Hartmann, S.; Ebelin, M.-E.; Burtin, P.; Rappersberger, K.; Komar, M.; Wolff, K. 2003: Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. Clinical Pharmacokinetics 42(14): 1305-1314
Edwards, G.; Eckland, D.J.A. 1999: Pharmacokinetics of pioglitazone in patients with renal impairment. Diabetologia 42(Suppl 1): A230
Kearns, G.L.; Bradley, J.S.; Abdel Rahman, S.; Jacobs, R.F.; Ppru Network 1999: Pharmacokinetics of pleconaril in neonates. Clinical Pharmacology and Therapeutics 65(2): 140
Courtney, R.; Sansone, A.; Statkevich, P.; Martinho, M.; Richards, W.; Laughlin, M. 2003: Pharmacokinetics of posaconazole in subjects with varying degrees of renal insufficiency. Clinical Pharmacology and Therapeutics 73(2): P45
Bockbrader, H.N.; Posvar, E.L.; Hunt, T.; Randinitis, E.J. 2004: Pharmacokinetics of pregabalin and a concomitantly administered oral contraceptive show no-drug drug interaction. Epilepsia 45(Suppl 3): 153
V.Q.oc Binh; Bui Tri Cuong; Bui Dai; Dinh Ngoc Duy; Travers, T.; Rieckmann, K.H.; Edstein, M.D. 2003: Pharmacokinetics of primaquine in healthy Vietnamese volunteers after a single oral primaquine dose with and without food. American Journal of Tropical Medicine and Hygiene 69(3 Suppl): 295
Paterson, A.C.; Shulkes, A.; Baldwin, G.S. 2000: Pharmacokinetics of progastrin6-80 in sheep. Regulatory Peptides 94(1-3): 53, 25 October
Sica, D.A.; Manowitz, N.R. 2003: Pharmacokinetics of propranolol following single and multiple-dosing with Inderal-LA or a chrontherapeutic form of propranolol. American Journal of Hypertension 16(5 Part 2): 128A-129A
Jendle, J.; Himmelmann, A.; Mellen, A.; Wollmer, P.; Petersen, A.H.; Dahl, U.L. 2001: Pharmacokinetics of pulmonary insulin in healthy smokers and non-smokers. Diabetologia 44(Suppl 1): A213
Horne, M.K.; Chang, R. 2003: Pharmacokinetics of pulse-sprayed recombinant tissue plasminogen activator for deep venous thrombosis. Thrombosis Research 111(1-2): 111-114
Noker, P.E.; Lin, T.H.; Smith, A.C.; Page, J.G. 2000: Pharmacokinetics of pyroxamide , a hybrid polar compound, in beagle dogs. Proceedings of the American Association for Cancer Research 41: 772
Hutchinson, O.C.; Collingridge, D.R.; Barthel, H.; Price, P.M.; Aboagye, E.O. 2003: Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. Current Pharmaceutical Design 9(11): 917-929
Fujimura, A.; Sasaki, M.; Sudoh, T. 2004: Pharmacokinetics of ranitidine and nizatidine in very elderly patients. Clinical Pharmacology and Therapeutics 75(2): P10
Erichsen, L.; Klitgaard, T. 2003: Pharmacokinetics of recombinant factor VIIa in adults with haemophilia A A modeling and simulation approach. Clinical Pharmacology and Therapeutics 73(2): P22
Braeckman, R.A.; Dietz, C.; Whitehouse, M.J.; Laham, R.J.; Simons, M.; Leimbach, M.; Chronos, N.A. 1999: Pharmacokinetics of recombinant fibroblast growth factor-2 after intracoronary administration in patients with severe coronary artery disease in a Phase I study. European Heart Journal 20(ABSTR Suppl ): 374
Hahn, T.W.; Henneberg, S.W.; Holm Knudsen, R.J.; Eriksen, K.; Rasmussen, S.N.; Rasmussen, M. 2000: Pharmacokinetics of rectal acetaminophen after repeated dosing in children. Pharmacotherapy 20(10): 1231
Hatorp, V.; Hasslacher, C.; Clauson, P. 1999: Pharmacokinetics of repaglinide in type 2 diabetes patients with and without renal impairment. Diabetologia 42(Suppl 1): A242
Jaruratanasirikul, S.; Sriwiriyajan, S. 1999: Pharmacokinetics of rifampicin administered alone and with indinavir. Journal of Antimicrobial ChemoTherapy 44(Suppl A): 58
Marshall, J.D.; Kauffman, R.E.; Keung, A.; Johnson, K.M.; Abdel Rahman, S.; Kearns, G.L. 1999: Pharmacokinetics of rifapentine in adolescents. Clinical Pharmacology and Therapeutics 65(2): 139
Doshi, S.; Ngo, L.Y.; Sarikaya, N.; Shabooti, M.; Eschenberg, M.; Cesano, A.; Perotti, B. 2003: Pharmacokinetics of rituximab and epratuzumab during concomitant administration of the two antibodies in patients with B-cell NHL. Blood 102(11): 644a
Davies, N.M.; Teng, X.W.; Skjodt, N.M. 2003: Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clinical Pharmacokinetics 42(6): 545-556
Edwards, D.J.; Prescilla, R.P.; Fratarelli, D.A.; Haritos, D.; Aranda, J.V. 2004: Pharmacokinetics of rofecoxib in children. Clinical Pharmacology and Therapeutics 75(2): P73
Thompson, K.; Zussman, B.; Miller, A.; Jorkasky, D.; Freed, M. 1999: Pharmacokinetics of rosiglitazone are unaltered in hemodialysis patients. Clinical Pharmacology and Therapeutics 65(2): 186
Pageaux, G.; Micallef, J.; Levron, J.C.; Lacarelle, B.; Le Moing, J.P.; Blin, O. 2000: Pharmacokinetics of sabeluzole, and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. Fundamental and Clinical Pharmacology 14(3): 279
Reid, J.M.; Bolterman, S.A.; Bagniewski, P.; Ames, M.M. 2002: Pharmacokinetics of safingol and fenretinide in rats. Proceedings of the American Association for Cancer Research 43: 427
Grub, S.; Schwarzwald, H.L.; Kline, M.W.; Jorga, K. 2002: Pharmacokinetics of saquinavir in children during long term treatment. Pediatric Infectious Disease Journal 21(7): 712-713
Vouillamoz Lorenz, S.; Buclin, T.; Lejeune, F.; Bauer, J.; Leyvraz, S.; Decosterd, L.A.thur 2003: Pharmacokinetics of satraplatin , an oral platinum complex under daily oral administration for 5 or 14 days. Anticancer Research 23(3C): 2757-2766
Morello, K.C.; Wurz, G.T.; DeGregorio, M.W. 2003: Pharmacokinetics of selective estrogen receptor modulators. Clinical Pharmacokinetics 42(4): 361-372
Hiemke, C.; Härtter, S. 2000: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology and Therapeutics 85(1): 11-28
Abolfathi, Z.; Vallee, F.; Masson, E. 2003: Pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. Clinical Pharmacology and Therapeutics 73(2): P65
Dresser, M.; Lindert, K.; Lin, D.; Gidwani, S.; Gupta, S.K.; Modi, N.B. 2004: Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology and Therapeutics 75(2): P32
Swaisland, H.C.; Smith, R.; Jones, H.; Farebrother, J.; Laight, A. 2001: Pharmacokinetics of single and multiple oral doses of ZD1839 , a specific epidermal growth factor receptor tyrosine kinase inhibitor , in healthy male volunteers. European Journal of Cancer 37(Suppl 6): S67
Dewey, C.W.; Boothe, D.M.; Wilkie, W.S. 2001: Pharmacokinetics of single-dose oral and intravenous mycophenolate mofetil administration in normal dogs. Journal of Veterinary Internal Medicine 15(3): 304
Ul'yanenko, S.E.; Yadrovskaya, V.A.; Savina, E.P.; Bratsev, V.A.; Borisov, G.I. 2000: Pharmacokinetics of sodium iodine-131 dodecaborate in mice with melanoma B-16. Khimiko-Farmatsevticheskii Zhurnal 34(5): 12-13
Cimino, C.O.; Shelnutt, S.R.; Wiggins, P.; Crook, T.; Zhang, Z.; Badger, T.M. 2001: Pharmacokinetics of soy isoflavone sulfates in men and women fed a soy beverage. FASEB Journal 15(5): A1099
Bellibas, S.E.; Price, R.W.; Sheiner, L.; Staprans, S.; Kates, R.E.; Aweeka, F. 1999: Pharmacokinetics of stavudine in cerebrospinal fluid of HIV infected subjects using sparse sampling. Clinical Pharmacology and Therapeutics 65(2): 161
Stass, H.; Sachse, R.; Heinig, R.; Zuehlsdorf, M.; Horstmann, R. 1999: Pharmacokinetics of steroid hormons in oral contraceptives are not altered by oral moxifloxacin. Journal of Antimicrobial ChemoTherapy 44(Suppl A): 138-139
Cicciarelli, N.; Murray, T.G.; Hayden, B.C.; Hernandez, E.; Milne, P.; Feuer, W.; Parel, J.M. 2001: Pharmacokinetics of subconjunctivally administered cyclosporine A Local delivery prior to chemotherapy for retinoblastoma. IOVS Investigative Ophthalmology and Visual Science 42(4): S332
Gasparetto, C.; Chao, N.J.; Horwitz, M.E.; Moore, J.O.; Decastro, C.; Gockerman, J.; Sullivan, K.; Rooney, B.; Houser, L.; Anderson, E.; Hale, G.; Toaso, B.; Riz 2003: Pharmacokinetics of subcutaneous alemtuzumab in a patient with myeloma. Blood 102(11): 385b
Ogden, A.; Zhang, C.; Wientjes, M.G.; Au, J.L.S. 2002: Pharmacokinetics of suramin in rats. Proceedings of the American Association for Cancer Research 43: 427
Stewart, J.J.; Berkel, H.J.; Parish, R.C.; Simar, M.R.; Wilson, J.T.; Bocchini, J.A.Jr 2000: Pharmacokinetics of sustained release bupropion in adolescent smokers and nonsmokers. Journal of Clinical Pharmacology 40(9): 1057
Borysko, K.Z.; Bidanset, D.J.; Kern, E.R.; Zemlicka, J.; Drach, J.C. 2002: Pharmacokinetics of synguanol in rats Oral bioavailability of a cytomegalovirus agent. Antiviral Research 53(3): A62
Noker, P.E.; Gorman, G.S.; Page, J.G.; Torti, S.V.; Torti, F.M.; Brechbiel, M.; Schweikart, K.M.; Tomaszewski, J.E. 2003: Pharmacokinetics of tachpyr in rats. Proceedings of the American Association for Cancer Research 44: 337
Undre, N.A.; Stevenson, P.; Schäfer, A. 1999: Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplantation Proceedings 31(7a): 21s-24s
Hariharan, S.; Tomlanovich, S.; Filo, R.; Wisemandle, W.; Dessimoz, M.; Bekersky, I.; Townsend, R. 2001: Pharmacokinetics of tacrolimus and sirolimus in stable renal transplant recipients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 893A
Undre, N.A.; Stevenson, P.J. 2002: Pharmacokinetics of tacrolimus in heart transplantation. Transplantation Proceedings 34(5): 1836-1838
Webb, N.J.A.; Stevenson, P.J.; Lewis, M.A.; Postlethwaite, R.J.; Bradbury, M.G.; Undre, N. A. 2002: Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplantation Proceedings 34(5): 1948-1950
Shishido, S.; Asanuma, H.; Tajima, E.; Honda, M.; Nakai, H. 2001: Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplantation Proceedings 33(1-2): 1066-1068
Braun, F.; Schütz, E.; Peters, B.; Talaulicar, R.; Grupp, C.; Undre, N.; Schäfer, A.; Armstrong, V.W.; Oellerich, M.; Ringe, B. 2001: Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplantation Proceedings 33(3): 2127-2128
Yu, Z.; Sefton, J.; Lew-Kaya, D.; Walker, P.; Yu, D.; Tang-Liu, D.D.-S. 2003: Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. Clinical Pharmacokinetics 42(10): 921-929
Lee, M.-J.; Maliakal, P.; Chen, L.; Meng, X.; Bondoc, F.Y.; Prabhu, S.; Lambert, G.; Mohr, S.; Yang, C.S. 2002: Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 11(10 Part 1): 1025-1032
Kirstein, M.N.; Gajjar, A.; Thompson, S.; Nair, G.; Fouladi, M.; Heideman, R.L.; Stewart, C.F. 2001: Pharmacokinetics of temozolomide and metabolites in children with primary central nervous system tumors. Proceedings of the American Association for Cancer Research 42: 653
Covey, J.M.; Chan, K.K.; Chiu, M. 2000: Pharmacokinetics of tempol and reduced tempol in the rat as measured by a specific GC/MS assay. Proceedings of the American Association for Cancer Research 41: 705
Turncliff, R.; Pollack, G.M.; Brouwer, K.L.R. 2003: Pharmacokinetics of terfenadine and fexofenadine in sandwich-cultured rat hepatocytes. Drug Metabolism Reviews 35(Suppl 2): 216
Ericsson, H.; Bergstrand, S.; Fryklund, L.; Hamren, B.; Heijer, M.; Ohman, P. 2003: Pharmacokinetics of tesaglitazar in healthy male subjects. Diabetes 52(Suppl 1): A118
Makanga, M.; Falade, C.O.; Premji, Z.; Bwika, J.; Marsh, K.; Lefevre, G.; Denouel, Y.; Gbotosho, G.O.; Happi, C.T.; Ogunkunle, O.O.; Falade, A.G.; Quattrocchi, E.; Ibarra, D.P.lacios, P.; Stockmeyer, M. 2003: Pharmacokinetics of the 6-dose regimen of co-artemether in African infants and children with uncomplicated Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 69(3 Suppl): 485
Trenk, D.; Wiessner, M.; Grewe, R.; Eschenbruch, E.M.; Tollenaere, P.J.; Roskamm, H.; Jaehnchen, E. 2001: Pharmacokinetics of the NO-releasing drug molsidomine before and after cardiac bypass surgery. Clinical Pharmacology and Therapeutics 69(2): P87
Jahnchen, E.; Seiler, K.U.; Brennscheidt, U.; Heintz, B.; Trenk, D. 2001: Pharmacokinetics of the analgesic tilidine in terminal renal failure. Clinical Pharmacology and Therapeutics 69(2): P54
Noker, P.E.; Lin, T.H.; Page, J.G.; Burke, T.G.; Schweikart, K.M.; Rhie, J.K. 2002: Pharmacokinetics of the camptothecin analog, DB-67, in mice, rats, and dogs. Proceedings of the American Association for Cancer Research 43: 425
Fleming, A.B.; Saltzman, W.M. 2002: Pharmacokinetics of the carmustine implant. Clinical Pharmacokinetics 41(6): 403-419
Smith,J.N.; Wang,J.; Lin,Y.H.; Timchalk,C. 2010: Pharmacokinetics of the chlorpyrifos metabolite 3,5,6-trichloro-2-pyridinol in rat saliva. Toxicological Sciences 3(2): 315-325
Sparreboom, A.; Brouwer, E.; Loos, W.J.; De Bruijn, P.; Nooter, K.; Stoter, G.; Verweij, J. 1999: Pharmacokinetics of the docetaxel vehicle polysorbate 80 The clinical significance of serum esterase-sensitive degradation. Proceedings of the American Association for Cancer Research 40: 584
Anadon, A.; Anton, M.R.; Martinez, M.A.; Martinez, M.; De La Cruz, C.O.; Martinez Larranaga, M.R. 2003: Pharmacokinetics of the fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites after oral dosing in chickens. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 115-116
Perkins, S.L.; Yang, C.H.; Guo, H.; Ashton, P.; Jaffe, G.J. 1999: Pharmacokinetics of the ganciclovir implant in the silicone filled eye. IOVS Investigative Ophthalmology and Visual Science 40(4): S87
Jungheinrich, C.; Scharpf, R.; Wargenau, M.; Dilger, C.; Bepperling, F. 2002: Pharmacokinetics of the generic formulation Propofol 1% Fresenius in comparison with the original formulation 1%. Clinical Drug Investigation 22(7): 417-427
Reyneke, G.; Sultan, E.; Perret, C.; Leroy, N.; Scholtz, H. 2001: Pharmacokinetics of the ketolide telithromycin in adolescent patients with respiratory tract infections. International Journal of Antimicrobial Agents 17(Suppl 1): S36
Drolet, D.W.; Tucker, C.; Tinnermeier, D.; Hu, N.; Jensen, G.; Bendele, R. 2002: Pharmacokinetics of the liposome encapsulated thymidylate synthase inhibitor GS7904L in mice and dogs. Proceedings of the American Association for Cancer Research 43: 211
Hennessy, D.R.; Alvinerie, M.R. 2002: Pharmacokinetics of the macrocyclic lactones Conventional wasdom and new paradigms. Vercruysse, J , Reprint Author, Rew, R S Macrocyclic lactones in antiparasitic therapy: 97-123
Benson, C.; Raynaud, F.; O'donnell, A.; Gianella Borradori, A.; Westwood, R.; Mcclue, S.; Workman, P.; Judson, I. 2002: Pharmacokinetics of the oral cyclin dependent kinase inhibitor CYC202 in patients with cancer. Proceedings of the American Association for Cancer Research 43: 273
Grind, M.; Hamren, B.; Baathe, S.; Wollbratt, M.; Eriksson, U.G. 2002: Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation receiving long-term treatment A population analysis by nonlinear mixed effect modeling. Clinical Pharmacology and Therapeutics 71(2): P31
Lokiec, F.; Goldwasser, F.; Santoni, J.; Gauzan, M.F.; Weill, S.; Misset, J.L. 1999: Pharmacokinetics of the oxaliplatin /topotecan combination Prelminary data of an ongoing phase I trial. Proceedings of the American Association for Cancer Research 40: 82
Lyness, W.; Tyler, J.; Lawrence, A. 2001: Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in subjects with impaired hepatic or renal function. Diabetologia 44(Suppl 1): A 15
Lyness, W.; Tyler, J.; Lawrence, A. 2001: Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, is independent of hepatic function. Diabetes 50(Suppl 2): A442
Hauns, B.; Huennemeyer, A.; Siegmund, W.; Waitzinger, J.; Hermann, R.; Zech, K.; Bethke, T.D. 2004: Pharmacokinetics of the selective PDE4 inhibitor Roflumilast and its active metabolite Roflumilast N-oxide are not affected by concomitant budesonide, salbutamol, or erythromycin. Journal of Allergy and Clinical Immunology 113(2 Suppl): S222
Lønning, P.; Pfister, C.; Martoni, A.; Zamagni, C. 2003: Pharmacokinetics of third-generation aromatase inhibitors. Seminars in Oncology 30(4 Suppl 14: 23-32
Kraft, W.K.; Bonner, H.S.; Chervoneva, I.; Waldman, S.A.; Shaw, L.M.; Greenberg, H.E. 2002: Pharmacokinetics of three subcutaneously administered formulations of amifostine. Clinical Pharmacology and Therapeutics 71(2): P12
Zhang, J.Y.; Li, J.Y.; Miao, X.L.; Zhou, X.Z.; Li, J.S.; Dong, P.C.; Xu, Z.Z. 2003: Pharmacokinetics of tilmicosin in sheep. Toxicology 191(1): 48-49, September 15th
Sabo, J.P.; Macgregor, T.R.; Lamson, M.J.; Baldwin, J.; Borin, M. 2001: Pharmacokinetics of tipranavir and nevirapine A pharmacokinetic interaction study in healthy volunteers. Antiviral Research 51(1): 75-76
Pinnell, S.R.; Yang, H.; Omar, M.; Montiero Riviere, N.; Levine, M. 2000: Pharmacokinetics of topical L-ascorbic acid in skin. Journal of Investigative Dermatology 114(4): 884
Koevary, S.B. 2003: Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Current Drug Metabolism 4(3): 213-222
Kirstein, M.N.; Furman, W.L.; Bernstein, M.; Steuber, C.P.; Becton, D.; Baruchel, S.; Stewart, C.F. 2001: Pharmacokinetics of topotecan in children with refractory acute leukemia. Proceedings of the American Association for Cancer Research 42: 538
Whitacre, C.M.; Li, X.; Ingalls, S.T.; Hoppel, C.L.; Berger, N.A. 1999: Pharmacokinetics of topotecan in human cell lines. Proceedings of the American Association for Cancer Research 40: 110
Cole, D.E.; Balis, F.M.; Goodspeed, W.; Drbohlav, N.; Wilson, W.H. 2002: Pharmacokinetics of total and free etoposide in dose-adjusted EPOCH chemotherapy. Proceedings of the American Association for Cancer Research 43: 429
Taber, E.; Tan, L.; Ross, M.; Chao, C. 2000: Pharmacokinetics of total and ionized magnesium in preterm labor and PIH subjects. American Journal of Obstetrics and Gynecology 182(1 Part 2): S146
Giorgi,M.; Saccomanni,G.; Andreoni,V. 2010: Pharmacokinetics of tramadol after epidural administration in horses. Journal Of Equine Veterinary Science: 1, 44-46
Izzedine, H.; Launay-Vacher, V.; Abbara, C.; Aymard, G.; Bassilios, N.; Deray, G. 2002: Pharmacokinetics of tramadol in a hemodialysis patient. Nephron 92(3): 755-756
Thompson, J.P.; Rowbotham, D.J. 2002: Pharmacokinetics of transdermal fentanyl. Anesthesia and Analgesia 95(3): 781
Ghahramani, P.; Lennon, S.M.; Leyland Jones, B.; Gelmon, K. 2003: Pharmacokinetics of trastuzumab in combination with paclitaxel given every 3 weeks in women with HER2 positive metastatic breast cancer. Clinical Pharmacology and Therapeutics 73(2): P83
GaiChunLei; ZhuAnCheng; LiTianBao; YeHaiBin; XuLa; WangYongQiang 2010: Pharmacokinetics of trimethoprim in Japanese flounder. Fisheries Science ( Dalian): 1, 15-18
Brown, F.; Banken, L.; Saywell, K.; Arum, I. 1999: Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clinical Pharmacokinetics 37(2): 167-176
Czock, D.; Scholle, C.; Rasche, M.; Kwan, J.; Brown, F.; Buhles, W.; Banken, L.; Keller, F. 2001: Pharmacokinetics of valganciclovir in renal impairment and hemodialysis. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 929A
Yap, K.Y.L.; Low, C.L.; Lye, W.C. 2002: Pharmacokinetics of vancomycin in Asian patients undergoing intermittent hemodiafiltration. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 238A
Blowey, D.L.; Warady, B.A.; Manley, H.J.; Frye, R.F.; Smith, C. 2003: Pharmacokinetics of vancomycin in children receiving peritoneal dialysis. Clinical Pharmacology and Therapeutics 73(2): P38
Turgeon, J.; Lessard, E.; Yessine, M.A.; Hamelin, B.A. 1999: Pharmacokinetics of venlafaxine in subjects with extensive or poor CYP2D6 activity. Clinical Pharmacology and Therapeutics 65(2): 171
Bon, C. 2003: Pharmacokinetics of venom toxins and their modification by antivenom therapy. Journal of Toxicology Toxin Reviews 22(1): 129-138
Armand, J.P.; Fumoleau, P.; Marty, M.; Variol, P.; Pinel, M.C.; Picard, M.; Puozzo, C. 2001: Pharmacokinetics of vinflunine, a novel vinca alkaloid, during the phase I dose escalation study. Proceedings of the American Association for Cancer Research 42: 381
Cass, L.M.; Efthymiopoulos, C.; Bye, A. 1999: Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clinical Pharmacokinetics 36(Suppl 1): 1-11
Sallee, F.R.; Miceli, J.J.; Wilner, K.D.; Robarge, L. 2000: Pharmacokinetics of ziprasidone in children and adolescents with Tourettes syndrome. European Neuropsychopharmacology 10(Suppl 3): S289
Miceli, J.J.; Murray, S. 2003: Pharmacokinetics of ziprasidone in pediatric versus adult subjects. European Neuropsychopharmacology 13(Suppl 4): S338
Mcjilton, J.S.; Ramsay, R.E.; Vasquez, D.; Wilder, B.J.; Sachellares, C.; Browne, T. 2000: Pharmacokinetics of zonisamide Results from a randomized double-blind multi-center placebo controlled study. Epilepsia 41(Suppl 7): 224
Mangiafico, S.; Maltese, A.; Cro, M.; Bucolo, C. 2001: Pharmacokinetics profile of topical cloricromene in rabbit eye. IOVS Investigative Ophthalmology and Visual Science 42(4): S175
Xie, S.; Fedoruk, M.; Adomat, H.; Skov, K.; Guns, E. 2001: Pharmacokinetics studies in mice with cesium chloride, a possible high pH therapeutic reagent for prostate cancer. Proceedings of the American Association for Cancer Research 42: 381
Andresen, I.; Bolli, R.; Spath, P.; Bender, K.; Morell, A. 2002: Pharmacokinetics, Safety and Tolerability of a Novel Liquid Intravenous Immunoglobulin Formulation. Blood 100(11): Abstract No. 3651
Vallabhajosula, S.; Kostakoglu, L.; Hamacher, K.A.; Brandman, S.; Bander, N.H.; Goldsmith, S.J. 2003: Pharmacokinetics, biodistribution and radiation dosimetry of radiolabeled anti-PSMA antibody Comparison of 111In-DOTA-J591 with 177Lu-DOTA-J591. Journal of Nuclear Medicine 44(5 Suppl): 322P
Li, J.S.; Sanders, S.P.; Perry, A.E.; Stinnett, S.S.; Darling, E.M.; Ungerleider, R.M.; Jaggers, J.; Bokesch, P.; Wheeler, A.; Anderson, P.A.W. 2000: Pharmacokinetics, efficacy, and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Circulation 102(18): 2; 599
Porter, J.B.; Waldmeier, F.; Bruin, G.; Shah, F.; Hazell, K.; Warrington, S.; Delage, S.; Sechaud, R.; Peter, R.; Ford, J.; Alberti, D.; Gross, G.; Schran, H. 2003: Pharmacokinetics, metabolism and elimination of the iron chelator drug ICL670 in beta-thalassemia patients. Blood 102(11): 5b
Wilkinson, G.P.; Loadman, P.M.; Jenkins, T.C.; Taylor, J.; Shnyder, S.D.; Cooper, P.A.; Thurston, D.E. 2003: Pharmacokinetics, metabolism glutathione reactivity of SJG-136. British Journal of Cancer 88(Suppl 1): S29
Shin, S.U.; Cho, H.M.; Kim, H.J.; Kwon, Y.K.; Kim, T.W.; Kim, J.; Kang, Y.S.; Iruela Arispe, L.; Morrison, S.L.; Rosenblatt, J.D. 2002: Pharmacokinetics, organ distribution, and efficacy of recombinant murine endostatin in mice Localization to kidney cortex. Proceedings of the American Association for Cancer Research 43: 27
Lees, P.; Aliabadi, F.S.ojaee 2002: Pharmacokinetics, pharmacodynamics and PK-PD integration of danofloxacin in sheep biological fluids. British Journal of Pharmacology 136(Proceedings Suppl): 25P
De Vries, M.H.; De Haes, J. Udo 1999: Pharmacokinetics, pharmacodynamics and tolerance of SLV 307 after single oral administration in healthy male volunteers. Clinical Pharmacology and Therapeutics 65(2): 165
Watson, J.; Stass, H.; Kubitza, D. 2001: Pharmacokinetics, safety and tolerability of a new intravenous formulation of moxifloxacin in healthy male volunteers. International Journal of Antimicrobial Agents 17(Suppl 1): S30
Stass, H.; Kubitza, D.; Schühly, U. 2001: Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clinical Pharmacokinetics 40(Suppl 1): 1-9
Gutierrez Puente, Y.; Tari, A.M.; Stephens, C.; Rosemblum, M.; Ford, R.; Guerra, R.T.; Lopez Berestein, G. 1999: Pharmacokinetics, safety, tissue distribution and antitumoral activity of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. Proceedings of the American Association for Cancer Research 40: 299
Feng, L.; Wang, L.; Jiang, X. 2010: Pharmacokinetics, tissue distribution and excretion of coumarin components from Psoralea corylifolia L. in rats. Archives of Pharmacal Research 33(2): 225-230
Degenhardt, T.P.; Khalifah, R.G.; Klaich, G.M.; Schotzinger, R.J. 2002: Pharmacokinetics, tolerability and biologic activity of oral PyridorinTM, a novel AGE inhibitor, in patients with type 1 diabetes and diabetic nephropathy. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 652A
Mallikaarjum, S.; Salazar, D.E.; Bramer, S.L. 2000: Pharmacokinetics, tolerability, and safety of aripiprazole following single and multiple oral dose administration. European Neuropsychopharmacology 10(Suppl 3): S306-S307
Castells, G.; Godoy, C.; De Miguel, J.M.; Cristofol, C.; Caballero, J.M. 2003: Pharmacokinetics/pharmacodynamics analysis of an oral powder-soluble formulation of 50% amoxicillin in pigs. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 110-111
Droumev, D.; Pashov, D.; Dimitrova, D.; Ivanova Gorcheva, S.; Nazarov, V.; Karanikolova, M.; Vesselova, S.; Cholakov, R. 2003: Pharmacokinetics/pharmacodynamics of enrofloxacin after oral and subcutaneous application in cats. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 105-106
Gremse, D.; Tolia, V.; Pan, W.J.; Kane, R.IIi; Karol, M.; Chiu, Y.; Pilmer, B.; Book, L. 2000: Pharmacokinetics/pharmacodynamics of lansoprazole in pediatric patients with symptomatic gastroesophageal reflux disease. JPGN 31(Suppl 2): S39
Smith, P.F.; Booker, B.M.; Pendyala, L. 2002: Pharmacokinetics/pharmacodynamics of mesna-mediated depletion of plasma cysteine. Clinical Pharmacology and Therapeutics 71(2): P12
Kaniwa, N.; Sai, K.; Saito, Y.; Hasegawa, R.; Shirao, K.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Ozawa, S.; Sawada, J.I.hi 2003: Pharmacokintics of irinotecan and its metabolites in Japanese cancer patients. Drug Metabolism Reviews 35(Suppl 2): 218
Yu, C.; Dent, P.; Grant, S. 2002: Pharmacologic PI3 Kinase inhibitors interact in a highly synergistic manner with the cyclin-dependent kinase flavopiridol to induce mitochondrial damage, caspase activation, and apoptosis in human leukemia cells. Proceedings of the American Association for Cancer Research 43: 602
Lewalter, T.; Lickfett, L.; Wolpert, C.; Yang, A.; Schimpf, R.; Luederitz, B. 2001: Pharmacologic and ablative hybrid-therapy in atrial fibrillation Relevance of intravenous propafenone testing. Journal of the American College of Cardiology 37(2 Suppl A): 139A
Marcucci, G.; Dai, G.; Klisovic, M.I.; Shen, T.; Liu, S.; Sher, D.A.; Lucas, D.; Whitman, S.P.; Vukosavljevic, T.; Zwiebel, J.A.; Frankel, S.R.; Grever, M.R.; Stock, W.; Chan, K. 2003: Pharmacologic and biologic assessment of GenasenseTM , a pro-apoptotic to Bcl-2 oligonucleotide, in combination with daunorubicin and cytarabine A phase I study in previously untreated elderly acute myeloid leukemia. Blood 102(11): 874a
So, A.; Lee, T.Y.m 2004: Pharmacologic and carbon dioxide reactivity of coronary circulation as determined by computed tomography perfusion. Journal of the American College of Cardiology 43(5 Suppl A): 320A
Molnar, I.; Hall, P.D.; Willoghby, T.; Mone, A.; Kreitman, R.J.; Frankel, A.E. 2000: Pharmacologic and immunologic studies of a diphtheria fusion protein in patients with relapsed or refractory AML. Blood 96(11 Part 1): 122a-123a
Olmos, G.; Alemany, R.; Boronat, M.A.; García-Sevilla, J.A. 1999: Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes. Annals of the new York Academy of Sciences 881: 144-160
Mazzotta, P.; Magee, L.A. 1999: Pharmacologic and non-pharmacologic management of nausea and vomiting of pregnancy; A systematic critical review of the safety and effectiveness of treatment. Clinical Pharmacology and Therapeutics 65(2): 199
Banoub, M.; Tetzlaff, J.E.; Schubert, A. 2003: Pharmacologic and physiologic influences affecting sensory evoked potentials: implications for perioperative monitoring. Anesthesiology 99(3): 716-737
Long, D.J.; Devantier, H.R.; Brennan, F.X.; Bryant, R.W.; Salemme, F.R.; Palmer, R.K. 2010: Pharmacologic antagonism of the oral aversive taste-directed response to capsaicin in a mouse brief access taste aversion assay. Journal of Pharmacology and Experimental Therapeutics 332(2): 525-530
Lukacs, G.L.; Durie, P.R. 2003: Pharmacologic approaches to correcting the basic defect in cystic fibrosis. New England Journal of Medicine 349(15): 1401-1404
Garcia, A.A.; Sumano, H.; Nunez, E. 2002: Pharmacologic basis of short term intravenous general anestesia in the equine. Veterinaria Mexico 33(3): 309-333
Wilson, S. 2000: Pharmacologic behavior management for pediatric dental treatment. Pediatric Clinics of North America 47(5): 1159-1175
Rogers, R.S.; Lue, T.F. 2000: Pharmacologic cavernosometry in an animal model of venous leakage impotence. Journal of Urology 163(4 Suppl): 202
Percy, W.H.; Merkwan, C.L. 1999: Pharmacologic characteristics of rabbit distal colonic mucosal epithelium and its innervation. Gastroenterology 116(4 Part 2): A917
Evans, D.H.; Gunderson, M.P. 1999: Pharmacologic characterization of an ETB endothelin receptor in the gills of the shark, Squalus acanthias. FASEB Journal 13(5 Part 2): A748
Escribá, P.V.; Ozaita, A.; García-Sevilla, J.A. 1999: Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods. Annals of the new York Academy of Sciences 881: 8-25
Morgan, A.U.; Domek, M.J. 2000: Pharmacologic concentrations of vitamin C inhibit the growth of Helicobacter pylori in vitro. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1278
Fletcher, C.V. 2001: Pharmacologic considerations for antiretroviral drug development in children. Antiviral Research 51(1): 19
Papich, M.G. 2000: Pharmacologic considerations for opiate analgesic and nonsteroidal anti-inflammatory drugs. Veterinary Clinics of North America. Small Animal Practice 30(4): 815
Calligaro, I.L.; Burman, C.A. 2001: Pharmacologic considerations in the neonate with congenital heart disease. Clinics in Perinatology 28(1): 209-222
Slavik, R.S.; Tisdale, J.E.; Borzak, S. 2001: Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Progress in Cardiovascular Diseases 44(2): 121-152
Stanczyk, F.Z.; Chaikittisilpa, S.; Roy, S. 2003: Pharmacologic deficiency in the Women's Health Initiative Study. Journal of Reproductive Medicine 48(6): 485-486
Bauer, V.; Rekalov, V.; Matyas, S. 2003: Pharmacologic differences and interactions between circular and longitudinal muscle layer of the guinea pig ileum. Journal of Pharmacological Sciences 91(Suppl I): 110P
Puskas, J.D. 2001: Pharmacologic drug combination in vagal-induced asystole. Official Gazette of the United States Patent and Trademark Office Patents 1243(1)
Sellers, E.M.; Romach, M.K.; Ngoc, A. Ho; Lu, S.; Kaplan, H.L.; Juurlink, D.N.; Du Souich, P. 2002: Pharmacologic effects and safety of single and multiple doses of tetrodotoxin. Clinical Pharmacology and Therapeutics 71(2): P16
Capparelli, C.; Morony, S.; Warmington, K.S.; Lacey, D.L.; Dunstan, C.R.; Kostenuik, P.J. 2000: Pharmacologic effects of a single treatment with osteoprotegerin on bone remodeling and bone density in normal rats. Journal of Bone and Mineral Research 15(Suppl 1): S171
Klein, B.D.; Barton, M.E.; Wolf, H.H.; White, H.S.eve 2001: Pharmacologic effects of antiepileptic drug treatment on c-Fos immunoreactivity in the 6-Hz psychomotor seizure model of partial epilepsy. Epilepsia 42(Suppl 7): 127
Sakwa, M.P.; Mccue, M.; Altshuler, J.M.; Timmis, S.B.; Duhaylongsod, F.G.; Ayers, G.M.; Goldstein, J.A. 2000: Pharmacologic electrical arrest with intermittent pacing facilitates off-pump bypass surgery. Journal of the American College of Cardiology 35(2 Suppl A): 341A
Meyers, C.D.; Kashyap, M.L. 2004: Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Current Opinion in Cardiology 19(4): 366-373
Zhao, L.; Elliott, G.T. 1999: Pharmacologic enhancement of tolerance to ischemic cardiac stress using monophosphoryl lipid A. a comparison with antecedent ischemia. Annals of the new York Academy of Sciences 874: 222-235
Sausville, E.A.; Alley, M.C.; Pacula Cox, C.M.; Hollingshead, M.G.; Waud, W.R.; Nakanishi, O. 2001: Pharmacologic evaluations of MS-275 , a novel benzamide structure with a unique spectrum of antitumor activity. Proceedings of the American Association for Cancer Research 42: 927
Alley, M.C.; Stinson, S.F.; Pacula Cox, C.M.; Camalier, R.F.; Phillipps, L.R.; Daw, T.W.; Sausville, E.A. 1999: Pharmacologic evaluations of a novel amino-substituted flavone exhibiting unique in vitro and in vivo anticancer activities. Proceedings of the American Association for Cancer Research 40: 119
Alley, M.C.; Stinson, S.F.; Pacula Cox, C.M.; Upadhyay, K.B.; Bradshaw, T.D.; Chua, M.S.; Stevens, M.F.G.; Sausville, E.A. 2000: Pharmacologic evaluations of fluorinated 2- benzothiazole analogs with unique anticancer activities. Proceedings of the American Association for Cancer Research 41: 813-814
Kanter, J.R.; Brunton, L.L. 2000: Pharmacologic evidence for a tyrosine kinase-mediated activation of cyclic AMP hydrolysis in ventricular myocytes and fibroblasts from rat heart. FASEB Journal 14(4): A592
Govindarajan, B.; Arbiser, J.L.; Bai, X.; Cerimele, F. 2003: Pharmacologic evidence of an autocrine angiopoietin2-tie-2 loop in the pathogenesis of hemangioma of infancy. Journal of Investigative Dermatology 121(1): 0013
Scarpellini, L.; Scarpellini, F.; Boccadoro, R. 2001: Pharmacologic induction of cervical ripening by systemic DHEA-S administration in post-term pregnancy. American Journal of Obstetrics and Gynecology 184(1): S126
Flanigan, A.; Murthy, S.; Yoshitake, H.; Osborne, B.; Traszkos, J.; Dinchuk, J. 1999: Pharmacologic inhibition and cyclooxygenase -2 gene knockout intensifies dextran sulfate -induced colitis in mice. Gastroenterology 116(4 Part 2): A880
Kern, T.S.; Engerman, R.L. 2000: Pharmacologic inhibition of diabetic retinopathy Comparison of aminoguanidine and aspirin. IOVS Investigative Ophthalmology and Visual Science 41(4): S114
Kamerath, C.D.; Masaki, T.; Leypoldt, J.K.; Mohammad, S.F.; Cheung, A.K. 2000: Pharmacologic inhibition of human vascular smooth muscle cell proliferation as a strategy for prevention of vascular access stenosis. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 187A
Weiss, A.; Goldman, S.; Ben Shlomo, I.; Shalev, E. 2001: Pharmacologic inhibition of matrix metalloproteinases in the late gestation fetal-maternal interface. American Journal of Obstetrics and Gynecology 185(6 Suppl): S150
Sarkaria, J.N.; Eshleman, J.S.; Carlson, B.L.; Mladek, A.C.; Kastner, B.D.; Shide, K.L. 2002: Pharmacologic inhibition of the mammalian target of rapamycin enhances the efficacy of fractionated radiation in U87 xenografts. Proceedings of the American Association for Cancer Research 43: 688
Deferrari, G.; Pontremoli, R.; Repetto, M.; Robaudo, C. 1999: Pharmacologic inhibition of the renin-angiotensin system and diabetic nephropathy. Crepaldi, G, Tiengo, A, Del Prato, S International Congress Series; Insulin resistance, metabolic diseases and diabetic complications 187-192
Dai, Yun; Yu, Chun Rong; Dent, Paul; Grant, Steven 2001: Pharmacologic inhibitors of the MEK/MAPK pathway dramatically potentiate UCN-01-induced apoptosis in diverse leukemia cell lines. Proceedings of the American Association for Cancer Research 42: 641
Jones, R.T.; Dearborn, A.S.; Uemura, N.; Lester, L.; Chiang, N.; Jacob, P.IIi; Mendelson, J. 2000: Pharmacologic interactions between transdermal selegiline and cocaine. Drug and Alcohol Dependence 60(Suppl 1): S102-S103, 1 December
Martin, George Reilly 2001: Pharmacologic intervention in the fibrotic response. IOVS Investigative Ophthalmology and Visual Science 42(4): S1
Harper, A.J.; Carlson, A.E.; Hille, B.; Babcock, D.F. 2002: Pharmacologic investigation of signaling pathways in bicarbonate-mediated acceleration of spermatozoan flagellar beat frequency. Biology of Reproduction 66(Suppl 1): 168
Nagy, L.; Szabo, S. 1999: Pharmacologic investigations on gastric mucosal cells. Gastroenterology 116(4 Part 2): A262
Pru, J.K.; Kollara, A.; Johnson, J.; Brown, T.J. 2003: Pharmacologic ligands of the aryl hydrocarbon receptor repress cell cycle regulatory genes in the decidua of early pregnancy. Biology of Reproduction 68(Suppl 1): 241-242
Simpson, B.S.; Papich, M.G. 2003: Pharmacologic management in veterinary behavioral medicine. Veterinary Clinics of North America. Small Animal Practice 33(2): 365-404 Vii
Williams, T.P.; Miller, B.D. 2003: Pharmacologic management of anxiety disorders in children and adolescents. Current Opinion in Pediatrics 15(5): 483-490
Boccuzzi, S.J.; Suppapanya, N.; Peverly, C.; Epstein, R.S. 1999: Pharmacologic management of cardiovascular disease in a United States insured population. Journal of the American College of Cardiology 33(2 Suppl A): 296A
Hardin, K.A.; Kallas, H.J.; McDonald, R.J. 2001: Pharmacologic management of the hospitalized pediatric asthma patient. Clinical Reviews in Allergy and Immunology 20(3): 293-326
Wein, A.J.; Rovner, E.S. 2002: Pharmacologic management of urinary incontinence in women. Urologic Clinics of North America 29(3): 537
Wu, J.; Fisher, R.S. 2003: Pharmacologic manipulations of hyperthermic spreading depression in immature hippocampal slices. Epilepsia 44(Suppl 9): 211-212
Kearney, B.P.; Gambertoglio, J.G. 1999: Pharmacologic modulation of P-glycoprotein expression An alternative approach to improve the penetration of drugs. Clinical Pharmacology and Therapeutics 65(2): 125
Staunton, M.; Havlik, H.A.; Schmid, P.G.; Hudetz, A.G.; Farber, N.E. 1999: Pharmacologic modulation of neuronal-vascular coupling in rat brain slices. Anesthesiology 91(3A): A732
Menegatti, E.; Chiara, M.; De Rosa, G.; Bellis, D.; Sena, L.M.; Roccatello, D. 1999: Pharmacologic modulation of the expression of the cell cycle regulatory proteins in an experimental model of mesangial nephritis. Nephrology Dialysis Transplantation 14(9): A26
Kao, R.L.; Chin, T.K.; Li, C.; Browder, W. 2001: Pharmacologic myocardial regeneration. Journal of Molecular and Cellular Cardiology 33(6): A56
Ibrahim, E.; Chin, T.; Davis, J.; Kao, R.L. 2002: Pharmacologic myocardial regeneration using 5-Aza-2deoxycytidine. FASEB Journal 16(4): A491
Yang, C.W.; Ahn, H.J.; Park, J.H.; Kim, Y.O.; Kim, Y.S.; Bang, B.K. 2000: Pharmacologic preconditioning using low-dose cyclosporine or FK506 in rat kidney with ischemia/reperfusion injury Possible role of heat shock protein70 as a mediator of ischemic tolerance. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 611A
Capparelli, E.V.; Hsyu, P.H.; Amantea, M.; Lane, J.R.; Williams, P.; Kerr, B. 2002: Pharmacologic predictors of long term HIV suppression in pediatric patients treated with nelfinavir. Clinical Pharmacology and Therapeutics 71(2): P4
Hamilton, B.D.; Streem, S.B. 1999: Pharmacologic prevention of uric acid calculi Comparison of agents with longterm followup. Journal of Endourology 13(Suppl 1): A20
Funatsu, T.; Goto, M.; Tanaka, H.; Usuda, S.; Miyata, K. 1999: Pharmacologic profile of YM548, a novel HMG-CoA reductase inhibitor, in HepG2 cells. Japanese Journal of Pharmacology 79(Suppl 1): 188P
Grover, G.J.; Bathala, M.; Parham, C. 2002: Pharmacologic profile of the mitochondrial KATP opener BMS-191095 in a canine model of infarction. FASEB Journal 16(4): A175
Grover, G.J.; Atwal, K.S. 2002: Pharmacologic profile of the selective mitochondrial-K(ATP) opener BMS-191095 for treatment of acute myocardial ischemia. Cardiovascular Drug Reviews 20(2): 121-136
Nash, N.; Ader, M.; Barrett, M.; Burstein, E.; Duggento, K.; Feddock, M.; Gibson, D.; Goodman, M.; Li, D.; Lu, Q.; Ma, J.; Moore, C.; Pace, M.; Pham, E.; Piu, F.; Saurez, M.; Spalding, T.; Sulie 1999: Pharmacologic profiling of GPCRs in a high-throughput functional assay designed to identify novel lead compounds. Society for Neuroscience Abstracts 25(1-2): 158
Hadden, M.K.; Walle, T.; Dix, T.A. 2003: Pharmacologic properties of a radiolabeled analogue of neurotensin. Biopolymers 71(3): 392-393
Bymaster, F.; Witcher, J.; Michelson, D.; Dittmann, R.W. 2003: Pharmacologic properties of atomoxetine A novel treatment for attention deficit/hyperactivity disorder. Pharmacopsychiatry 36(5): 216-217
Benini, R.; D'antuono, M.; Avoli, M. 2002: Pharmacologic properties of epileptiform synchronization in amygdala/entorhinal cortex networks in vitro. Epilepsia 43(Suppl 7): 128
Inan, U.U.; Ozturk, F.; Ermis, S.S. 2003: Pharmacologic pupil dilation in diabetic patients. Retina 23(2): 254-256
Reece, E. 2002: Pharmacologic rescue of aberrant MAP kinase signal transduction and apoptotic pathways in hyperglycemia-induced diabetic embryopathy. American Journal of Obstetrics and Gynecology 187(6 Suppl): S153
Taylor, M.J.; Hogema, B.M.; Jakobs, C.; Schutgen, R.B.H.; Froestl, W.; Snead, O.C.; Grompe, M.; Gibson, K.M. 2000: Pharmacologic rescue of lethal seizures in a murine knockout model of succinic semialdehyde dehydrogenase deficiency. American Journal of Human Genetics 67(4 Suppl 2): 39
Miller, G.A.; Radhakrishnan, J. 1999: Pharmacologic reversal of hepatorenal syndrome Potential use of beta-adrenergic blockade. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 384A
Galperin, J.; Elizari, M.; Chiale, P.; Torres Molina, R.; Ledesma, R.; Scapin, O.; Vazquez Blanco, M. 2000: Pharmacologic reversion of chronic atrial fibrillation with amiodarone predicts long-term maintenance of sinus rhythm. European Heart Journal 21(Abstract Suppl): 327
Orr, W.C.; Chen, C.L.; Sloan, S. 2000: Pharmacologic stimulation of salivation Its role in acid clearance. American Journal of Gastroenterology 95(9): 2429
Joannidis, M. 2003: Pharmacologic strategies for the prevention of acute renal failure. Intensivmedizin und Notfallmedizin 40(5): 350-355
Hendel, R.C.; Mahmarian, J.J.; Cerqueira, M.D.; Bateman, T.M.; Olmsted, A.; Leppo, J.A.; Iskandrian, A.E. 2003: Pharmacologic stress SPECT myocardial perfusion imaging with a selective A2A agonist Results of a pilot study comparing adenosine with CVT-3146. Circulation 108(17): IV636
Orsinelli, D.A.; Daniels, C.J. 1999: Pharmacologic stress echocardiography. Dobutamine and arbutamine stress testing. Cardiology Clinics 17(3): 461-479 Viii
Picano, E.; Trivieri, M.G. 1999: Pharmacologic stress echocardiography in the assessment of coronary artery disease. Current Opinion in Cardiology 14(6): 464-470
Chun, K.A.; Cho, I.H.; Won, K.J.; Lee, H.W.; Park, J.S.; Shin, D.G.; Kim, Y.J.; Shim, B.S. 2001: Pharmacologic stress-induced stunning Evaluation with quantitative gated SPECT. Journal of Nuclear Medicine 42(5 Suppl): 95P
Cherif, A.; Marrakchi, Z.; Klouz, A.; Chaouachi, S.; Belkahia, C.; Boukef-Larguèche, S. 2003: Pharmacologic study of monohydrated caffeine in the treatment of apnoea of premature infant. Archives de Pediatrie: Organe Officiel de la Societe Francaise de Pediatrie 10(6): 517-520
Whiting, P.J.; Wafford, K.A.; Mckernan, R.M. 2000: Pharmacologic subtypes of GABAA receptors based on subunit composition. Martin, David L Author, Olsen, Richard W Author GABA in the nervous sytem: The view at fifty years 113-126
Prophet Study, G. Working Group, O.T. Organ Transplantation, O.T. German Society, O.C.; Trautnitz, M.; Galiano, S.; Scheidt, W. 2002: Pharmacologic testing of the reversibility of an increased pulmonary vascular resistance with prostaglandin E1 before heart transplantation Final results of the multicenter prophet study. Journal of Heart and Lung Transplantation 21(1): 70
Vystavkina, G.V.; Pisarev, A.G.; Chaplygina, G.V.; Syr'eva, T.N. 2002: Pharmacologic therapy of cholestasis in patients with viral hepatitis. Pediatriya (Moscow) (5): 56-60
Weinberger, B.; Weiss, K.; Heck, D.E.; Laskin, D.L.; Laskin, J.D. 2001: Pharmacologic therapy of persistent pulmonary hypertension of the newborn. Pharmacology and Therapeutics 89(1): 67-79
Everett, A.V. 2002: Pharmacologic treatment of adolescent depression. Current Opinion in Pediatrics 14(2): 213-218
Fernstrom, M.H.; Fernstrom, J.D. 2000: Pharmacologic treatment of obesity in a primary care weight management center. International Journal of Obesity 24(Suppl 1): S174
Grieger, T.A.; Benedek, D.M.; Flynn, J. 2001: Pharmacologic treatment of patients hospitalized with the diagnosis of schizoaffective disorder. Journal of Clinical Psychiatry 62(1): 59-60
Boyer, T.D. 2001: Pharmacologic treatment of portal hypertension: past, present, and future. Hepatology 34(4 Part 1): 834-839
Gonzalez Suarez, B.; Guarner, C.; Minana, J.; Sola Vera, J.; Gallego, A.; Gomez, C.; Dedeu, J.M.; Sabat, M.; Villanueva, C.; Soriano, G.; Balanzo, J. 2000: Pharmacologic treatment of portal hypertension contributes to prevent community-acquired spontaneous bacterial peritonitis. Journal of Hepatology 32(Suppl 2): 42
Kreutzer, M.L.; Louie, S. 2001: Pharmacologic treatment of the adult hospitalized asthma patient. Clinical Reviews in Allergy and Immunology 20(3): 357-383
Demetri, G.D. 2000: Pharmacologic treatment options in patients with thrombocytopenia. Seminars in Hematology 37(2 Suppl 4: 11-18
Bonner, L.T.; Peskind, E.R. 2002: Pharmacologic treatments of dementia. Medical Clinics of North America 86(3): 657-674
Yamashita, K.; Upadhyay, S.; Osada, M.; Hoque, M.; Xiao, Y.; Sato, F.; Meltzer, S.J.; Sidransky, D. 2003: Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Proceedings of the American Association for Cancer Research 44: 441-442
Serghides, L.; Kain, K.C. 2000: Pharmacologic up-regulation of monocyte and macrophage CD36 enhances the clearance of non-opsonised Plasmodium falciparum-parasitised erythrocytes and decreases malaria induced TNF alpha secretion. American Journal of Tropical Medicine and Hygiene 62(3 Suppl): 208
Yagihashi, T.; Iwasaki, T.; Wakabayashi, Y.; Muramatsu, D.; Agawa, T.; Usui, M. 2001: Pharmacologic vitreolysis induced by intravitreal injection of tissue plasminogen activator in rabbits. IOVS Investigative Ophthalmology and Visual Science 42(4): S423
Mcconnell, A.; Williams, R.; Shivers, K.; Kulkarni, K.; Monjok, E.; Opere, C.; Ohia, S.E. 2004: Pharmacological Characterization Of Prostanoid FP-Receptors in Isolated Porcine Irides. FASEB Journal 18(4-5): Abstract 403
Hamann, M.; Richter, A. 2001: Pharmacological GABAA receptor manipulations in a basal ganglia output structure in a rodent model of paroxysmal dystonia. Naunyn-Schmiedeberg's Archives of Pharmacology 363(4): R94
Smith, B.T.; Khan, M.; Singh, I. 2000: Pharmacological Induction of Adrenoleukodystrophy related protein can compensate for a lack of functional ALDP in X-ALD. FASEB Journal 14(4): A253
Keller, S.A.; Hernandez Hopkins, D.; Cesarman, E. 2002: Pharmacological Inhibition of Constitutive NF-kappaB Activity Down-Regulates Common Pro-Survival Pathways in KSHV- and EBV-Infected Lymphomas and Prevents the Development of KSHV-Associated Lymphomas In Vivo. Blood 100(11): Abstract No. 2252
Sauter, A.; Rudin, M. 2000: Pharmacological MRI: a nebulous concept. Trends in Pharmacological Sciences 21(11): 422-423
Lee, H.C.; Middlekauff, E.H.; Asaumi, M.; Kawahara, S.; Sugimoto, H.; Satoh, Y.; Kirino, Y.; Kim, Y.I. 1999: Pharmacological action of E2020, a novel cholinesterase inhibitor, on neuromuscular transmission. Society for Neuroscience Abstracts 25(1-2): 2118
Liu, Geng Tao 2001: Pharmacological actions and clinical applications of Fructus schizandrae. Mori, Akitane, Satoh, Tetsuo Emerging Drugs Molecular aspects of Asian medicine 461-478
Sunagawa, M.; Kosugi, T.; Nakamura, M.; Sperelakis, N. 2000: Pharmacological actions of calmidazolium, a calmodulin antagonist, in cardiovascular system. Cardiovascular Drug Reviews 18(3): 211-221
Cuzzocrea, S.; Reiter, R.J. 2002: Pharmacological actions of melatonin in acute and chronic inflammation. Current Topics in Medicinal Chemistry 2(2): 153-165
Arnold, G.; Guzman, L.; Zhang, Q.; Unemori, E.; Huang, X. 2001: Pharmacological actions of recombinant human relaxin in impaired wound healing I Enhances macrophage infiltration in db/db mice. Wound Repair and Regeneration 9(2): 168
Arnold, G.; Guzman, L.; Cheng, J.; Unemori, E.; Huang, X. 2001: Pharmacological actions of recombinant human relaxin in impaired wound healing II Vasodilation in H-shaped ischemic wounds in rats. Wound Repair and Regeneration 9(2): 139-140
Nishida, S.; Satoh, H. 2004: Pharmacological actions of sinomenium actum, kampo medicine, on rat aorta. Journal of Pharmacological Sciences 94(Suppl 1): 212P
Miyata, S.; Ohkubo, Y.; Mutoh, S. 2004: Pharmacological actions of tacrolimus as an anti-rheumatic drug. Journal of Pharmacological Sciences 94(Suppl 1): 35P
Kulla, A.; Manahan Vaughan, D. 1999: Pharmacological activation of D1-like dopamine receptors inhibits depotentiation in the dentate gyrus of freely moving rats. Society for Neuroscience Abstracts 25(1-2): 469
H.L.we, D.; Heller, D.; Brekken, J.; Feeley, R.; Haines, M.; Troche, G.; Kim, Y.; Herrman, M.; Batugo, M.; Vekich, S.; Kania, R.; Mctigue, M.; Gonzalez, D.; Mueller, B.; Gregory, S.; Bender, S.; Shalinsky, D.R. 2002: Pharmacological activities of AG013736, a small molecule inhibitor of VEGF/PDGR receptor tyrosine kinases. Proceedings of the American Association for Cancer Research 43: 1082
Lee, Sang Hoon; Vora, Jayesh; De Menezes, Daniel Lopes; Wiesmann, Marion; Garrett, Evelyn; Aukerman, Lea; Heise, Carla 2003: Pharmacological activities of CHIR258, a small molecule inhibitor of growth factor tyrosine kinase receptors involved in angiogenesis and tumor cell proliferation. Proceedings of the American Association for Cancer Research 44: 934
Satoh, Y.miko; Nosaka, Emi; Ito, Kazuhiro; Nishi, Takahide; Yamaguchi, Takeshi 2000: Pharmacological activities of R-113281, a novel NK1, NK2 and NK3 receptor antagonist in vivo. Japanese Journal of Pharmacology 82(Suppl 1): 111P
Lee, J.W.; Baek, S.J.; Lee, S.M.; Han, M.D.; Kim, Y.H.; Bang, K.U.; Jeong, H. 2000: Pharmacological activities of the high and low molecular fractions extracted from several Basidiomycetes. Mycobiology 28(4): 208
Alcalde, S.; Flores, M.L.; Cordoba, O.L.; Hocht, C.; Taira, C. 2003: Pharmacological activity and phytochemical analysis of leaves from Chiliotrichum diffusum. Biocell 27(3): 395
Bymaster, F.P.; Perry, K.W.; Delapp, N.W.; Evans, D.C.; Falcone, J.F.; Moore, N.A.; Hemrick Luecke, S.K. 2003: Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors. Journal of Psychopharmacology 17(Suppl 3): A49
Sorokina, I.V.; Tolstikova, T.G.; Dolgikh, M.P.; Shul'ts, E.E.; Dushkin, A.V.; Karnatovskaya, L.M.; Chabueva, E.N.; Boldyrev, V.V. 2002: Pharmacological activity of complexes of nonsteroid anti-inflammatory drugs with glycyrrhizic acid, which were obtained through the methods of liquid-phase and solid-phase synthesis. Khimiko-Farmatsevticheskii Zhurnal 36(1): 12-13
Navarro, E.; Alonso, S.J.; San Martin, J. 2002: Pharmacological activity of mineral waters of Firgas. Methods and Findings in Experimental and Clinical Pharmacology 24(Suppl A): 128
Spasov, A.A.; Iezhitsa, I.N.; Bugaeva, L.I.; Anisimova, V.A. 1999: Pharmacological activity spectrum and toxic properties of benzimidazole derivatives A review. Khimiko-Farmatsevticheskii Zhurnal 33(5): 6-17
Crenshaw, T.D.; Schneider, D.K. 2001: Pharmacological additions of zinc to nursery diets and subsequent skeletal integrity in finishing gilts. Journal of Animal Science 79(Suppl 2): 78
Fernandez Pol, Jose, A. 2002: Pharmacological agent and method of treatment. Official Gazette of the United States Patent and Trademark Office Patents 1259(3)
Bleakman, D.; Helton, D.R.; Smriti, I.; Lodge, D.; Ornstein, P.L. 2001: Pharmacological agents. Official Gazette of the United States Patent and Trademark Office Patents 1247(1)
Lipson, V.V. 1999: Pharmacological agents affecting insulin resistance A review. Khimiko-Farmatsevticheskii Zhurnal 33(7): 13-18
Fernandez Pol, J.A.; Fernandez Pol, S. 2004: Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets. Official Gazette of the United States Patent and Trademark Office Patents 1287(2)
Doyle, M.ái.E.; Egan, J.M. 2003: Pharmacological agents that directly modulate insulin secretion. Pharmacological Reviews 55(1): 105-131
Kojima, S.; Nidaira, T.; Kouuchi, T.; Urano, A.; Ito, E. 1999: Pharmacological analyses of optically-detected slow depolarizing response in the pond snail, Lymnaea stagnalis. Society for Neuroscience Abstracts 25(1-2): 2174
Mahmoud, N.G.; Mueller, A.; Mckeating, J.A.; Strange, P.G. 2001: Pharmacological analysis of CCR5 receptors using -GTPgammaS binding. British Journal of Pharmacology 133(Proceedings Suppl): 192P
Higuchi, C.; Kudo, Y.; Morita, M. 2000: Pharmacological analysis of calcium oscillations in rat cortical type I astrocytes in culture stimulated with glutamate. Neuroscience Research Suppl (24): S106
Cheng, E.; Weisblat, D.A. 1999: Pharmacological analysis of cytoskeletal mechanisms in epiboly. Developmental Biology 210(1): 235
Peroutka, S. 2003: Pharmacological analysis of existing prophylatic migraine agents Inhibition of sympathetic nervous system activation as a common mechanism of action. Cephalalgia 23(7): 727
Martin, A.; Parsons, S.; Wilson, R.; Green, A.; Walls, S.; Giles, H.; Marshall, F. 2000: Pharmacological analysis of human GABAB and GABAB heterodimers expressed in CHO cells Allosteric modulation of agonists and antagonists by Ca2+. British Journal of Pharmacology 129(Proceedings Suppl): 82P
Adachi, A. 2002: Pharmacological analysis of inhibitory effect of sarpogrelate hydrochloride on human radial artery contraction. Hokkaido Journal of Medical Science 77(1): 57-62
Yoshida, M.; Inadome, A.; Ueda, S. 2002: Pharmacological analysis of neurotransmitters in lower urinary tract function. Japanese Journal of Pharmacology 88(Suppl 1): 12P
Reed, B.T.; Keyser, K.T.; Amthor, F.R. 1999: Pharmacological analysis of nicotinic receptors in rabbit retinal ganglion cells. IOVS Investigative Ophthalmology and Visual Science 40(4): S815
Gonchar, G.; Beregova, T. 2000: Pharmacological analysis of stimulation action of histamine on gastric secretion. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1174
Shiraishi, M.; Hirasawa, N.; Kobayashi, Y.; Oikawa, S.; Ohuchi, K. 1999: Pharmacological analysis of the mechanism of thapsigargin- and TPA-induced histamine production in murine macrophage RAW 2647 cells. Japanese Journal of Pharmacology 79(Suppl 1): 291P
Nishimaru, K.; Tanaka, Y.; Tanaka, H.; Shigenobu, K. 2000: Pharmacological analysis of the signal transduction pathway for alpha1-adrenoceptor-mediated negative inotropic response in adult mouse myocardia. Japanese Journal of Pharmacology 82(Suppl 1): 197P
Hosoyamada, M.; Toki, A.; Jutabah, P.; Endou, H. 2002: Pharmacological analysis of urate uptake pathways in HeLa cells. Japanese Journal of Pharmacology 88(Suppl 1): 209P
Kato, K.; Li, J.; Ikeda, J.I.; Morita, I.; Murota, S.I. 2000: Pharmacological analysis on the rise of the nuclear calcium by glutamate and its role in neuronal cell death. Japanese Journal of Pharmacology 82(Suppl 1): 153P
Reed, B.T.; Amthor, F.R.; Keyser, K.T. 2001: Pharmacological analysis shows multiple nAChR subtypes in rabbit retina and a possible role for the alpha7 subunit in directional selectivity. IOVS Investigative Ophthalmology and Visual Science 42(4): S677
Miller, K.A.; Witkin, J.M.; Ungard, J.T.; Gasior, M. 1999: Pharmacological and behavioral characterization of cocaine-kindled seizures in mice. FASEB Journal 13(5 Part 2): A1107
Manzanares, J.; Corchero, J.; Romero, J.; Fernández-Ruiz, J.J.; Ramos, J.A.; Fuentes, J.A. 1999: Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences 20(7): 287-294
Brevi, S.; Magistretti, J.; De Curtis, M. 2000: Pharmacological and biophysical characterisation of high-voltage-activated Ca2+ currents in endopiriform-nucleus neurones. European Journal of Neuroscience 12(Suppl 11): 382
Dassow, H.; Preiss, R. 2002: Pharmacological and cellular characterization of differing chemoresistance mechanisms in CCRF-CEM cells during selection for doxorubicin resistance. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 1): R123
Piccardi, N.; Piccirilli, A.; Choulot, J.; Chadoutaud, B.; Msika, P. 2004: Pharmacological and clinical activities of 5-alpha Avocuta application for the management of androgenic disorders. Journal of Investigative Dermatology 122(3): A57
Tanaka, K.; Muramoto, K. 2004: Pharmacological and clinical effect of T-614 , an anti-rheumatic drug. Journal of Pharmacological Sciences 94(Suppl 1): 35P
Kamataki, T. 2001: Pharmacological and clinical significance of cytochrome P450. Japanese Journal of Pharmacology 85(Suppl 1): 36P
Aritake, K.; Katsuyama, N.; Okano, Y.; Inoue, T.; Hayaishi, O.; Urade, Y. 2004: Pharmacological and crystallographic analyses of HQL-79 as an inhibitor for human hematopoietic prostaglandin D synthase. Journal of Pharmacological Sciences 94(Suppl 1): 205P
Nail Boucherie, K.; Marescaux, C.; Depaulis, A. 1999: Pharmacological and electrical stimulation of various sites of the superior colliculus differentially interrupt absence-seizures in the genetic absence epilepsy rat from Strasbourg. Society for Neuroscience Abstracts 25(1-2): 1351
Lavoie, C.; Hebert, T.E. 2001: Pharmacological and functional characterisation of beta1/beta2 adrenergic receptors heterodimer. FASEB Journal 15(5): A897
Dubin, A.E.; Huvar, R.; D'andrea, M.R.; Pyati, J.; Zhu, J.Y.; Joy, K.C.; Wilson, S.J.; Galindo, J.E.; Glass, C.A.; Luo, L.; Jackson, M.R.; Lovenberg, T.W.; Erlander, M.G. 1999: Pharmacological and functional characteristics of serotonin 5-HT3A receptor are specifically modified by 5-HT3B subunit. Society for Neuroscience Abstracts 25(1-2): 1205
Demchyshyn, L.; Colantonio, C.M.; Liao, L.C.; Tong, S.; Hahn, S.E.; Lee, D.K.H. 1999: Pharmacological and functional characterization of the human glucagon-like-peptide-2 receptor. Gastroenterology 116(4 Part 2): A601
Kishimoto, I.; Li, Y.; Harada, M.; Kuwahara, K.; Izumi, T.; Takahashi, N.; Kawakami, R.; Nakagawa, Y.; Nakanishi, M.; Adachi, Y.; Tanimoto, K.; Nakao, K. 2001: Pharmacological and genetic blockades of angiotensin II type 1A receptors markedly improve cardiac fibrosis in guanylyl cyclase A receptor knockout mice. Circulation 104(17): 2; 281
Hu, H.; Sato, T.; Liu, Y.; Johns, D.C.; O'rourke, B.; Marban, E. 1999: Pharmacological and histochemical distinctions between native cardiac mitochondrial KATP channels and molecularly-defined sarcolemmal KATP channels. Biophysical Journal 76(1 Part 2): A76
Ito, I.; Kimura, T.; Ito, E. 2000: Pharmacological and immunohistochemical analyses of the spontaneous oscillations in the tentacular ganglion of slug. Neuroscience Research Suppl (24): S160
Mcconnell, E.J.; White, G.W.; Brokaw, J.J.; Raess, B.U. 1999: Pharmacological and immunohistochemical characterization of calmodulin-stimulated -ATPase in cultured porcine aortic endothelial cells. FASEB Journal 13(5 Part 2): A862
Horinouchi, T.; Tanaka, Y.; Tsujitani, M.; Koike, K. 2004: Pharmacological and molecular analyses of beta-adrenoceptors in guinea-pig esophagus. Journal of Pharmacological Sciences 94(Suppl 1): 148P
Suzuki, H.; Takada, T.; Ogawa, K.; Ito, K.; Hirohashi, T.; Sugiyama, Y. 1999: Pharmacological and molecular biological characterization of the inducible nature of multidrug resistance associated protein 3. Hepatology 30(4 Part 2): 306A
Gonzalez, A.; Farre, R.; Mones, J.; Capella, G.; Clave, P. 1999: Pharmacological and molecular characterization of CCK receptors in the human lower esophageal sphincter. Gastroenterology 116(4 Part 2): A999
Wang, H.; Shi, H.; Deng, X.; Wang, Z. 1999: Pharmacological and molecular characterization of muscarinic acetylcholine receptor subtypes in human heart. Life Sciences 64(6-7): 590
Patel, V.; Xu, L.; Mortimer, J.; English, A.M.; Chan, C.C.; Kennedy, B.P. 2003: Pharmacological and molecular characterization of the diet-induced obese mouse. FASEB Journal 17(4-5): Abstract 337
Sarang, S.S.; Hsioa, L.L.; Yoshida, T.; Randall, J.; Cadet, R.; Valeras, A.; Clark, K.; Jensen, R.; Gullans, S. 2001: Pharmacological and molecular mechanisms of neuroprotection revealed through high throughput bioassays and DNA microarrays. FASEB Journal 15(4): A483
Gullans, S.; Sarang, S.; Yoshida, T.; Mueller, E.; Hsiao, L.L.; Randall, J.; Chow, G.; Cadet, R.; Kurella, M. 2001: Pharmacological and molecular mechanisms of renal cytoprotection revealed through high throughput bioassays and DNA microarrays. FASEB Journal 15(5): A851
Yunoki, T.; Teramoto, N.; Seki, N.; Ito, Y.; Naito, S. 2004: Pharmacological and molecular properties of human detrusor ATP-sensitive potassium channels. Journal of Urology 171(4 Suppl): 458
Tisdale, J.E.; Huang, M.B.; Borzak, S. 1999: Pharmacological and non-pharmacological risk factors for hypertensive crisis. Clinical Pharmacology and Therapeutics 65(2): 130
Villar, J.C.; Leon, H.; Nino, J.; Tahvanainen, K.U.O.; Kuusela, T.A.; Morillo, C.A. 1999: Pharmacological and non-pharmacological testing of baroreflex gain in healthy subjects. Neurology 52(6 Suppl 2): A342
Sommer, C. 2001: Pharmacological and nonpharmacological treatment of neuropathic pain. Sommer, Claudia , Reprint Author Pain in peripheral nerve diseases: 172-195
Janigro, D.; Marchi, N.; Cucullo, L.; Vezzani, A.; Hallene, K.L.; Kight, K.M.; Hossain, M.; Marroni, M. 2003: Pharmacological and pathological significance of MDR1 expression in human epileptic brain. Epilepsia 44(Suppl 9): 98
Jonker, J.W.; Wagenaar, E.; Buitelaar, M.; Mol, C.A.A.M.; Smit, J.W.; Schinkel, A.H. 2000: Pharmacological and physiological characterization of the organic cation transporter 1 using a knockout mouse model. Hepatology 32(4 Pt 2): 316A
Obolentseva, G.V.; Litvinenko, V.I.; Ammosov, A.S.; Popova, T.P.; Sampiev, A.M. 1999: Pharmacological and therapeutic properties of licorice preparations. Khimiko-Farmatsevticheskii Zhurnal 33(8): 24-31
Perucca, E. 2002: Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS drugs 16(10): 695-714
Dasgupta, S.C.; Gomes, A. 2004: Pharmacological and toxicological evaluation of Lates calcarifer skin extract. Indian Journal of Pharmacology 36(2): 119
Karaki, H. 2002: Pharmacological and toxicological experiments using human tissues Necessity and problems. Japanese Journal of Pharmacology 88(Suppl 1): 33P
Spasov, A.A.; Khamidova, T.V.; Bugaeva, L.I.; Morozov, I.S. 2000: Pharmacological and toxicological properties of adamantane derivatives A review. Khimiko-Farmatsevticheskii Zhurnal 34(1): 3-9
Kulkarni, S.K.; Jain, N.; Gupta, M.; Singh, A. 2000: Pharmacological and toxicological standardisation of an antihaemorrhoid phytomedicine. Phytomedicine 7(Suppl 2): 114-115
El Amri, Hamid; El Kabbaj, S.; El Amrani, A.; Lazrek, B.H. 2000: Pharmacological and toxicological studies on Globularia alypum and Zygophyllum gaetulum Two antidiabetics plants in the south of Morocco. Phytomedicine 7(Suppl 2): 122
Chang, F.C.T.; Hoffman, B.E.; Debus, S. 2002: Pharmacological antagonism of lethal effects induced by O-isobutyl S- ethylmethylphosphonothioate. Drug and Chemical Toxicology an International Journal for Rapid Communication 25(3): 321-337
Shoaib, M.; Gommans, J.; Stolerman, I.P. 2000: Pharmacological antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6 mice. Drug and Alcohol Dependence 60(Suppl 1): S201-S202, 1 December
Nielsen, S.; Moller, N.; Christiansen, J.S.; Jorgensen, J.O.L. 2000: Pharmacological antilipolysis restores insulin sensitivity during GH exposure. Growth Hormone and IGF Research 10(3): 134-135
Legrand, M.; Duvivier, C.; Calvez, V.; Ayinard, G.; Katlama, C.; Diquet, B. 2000: Pharmacological approach of GIGHAART. Fundamental and Clinical Pharmacology 14(3): 269
Seya, K.; Furukawa, K.I.; Taniguchi, S.; Takaya, Y.; Oshima, Y.; Niwa, M.; Motomura, S. 2001: Pharmacological approaches for calcium mobilization by vitisin C, a novel plant oligostilbene from Vitis coignetiae in the endothelial cells from rat aorta. Japanese Journal of Pharmacology 85(Suppl 1): 70P
Konstan, M.W.; Davis, P.B. 2002: Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Advanced Drug Delivery Reviews 54(11): 1409-1423
Fernández-López, J.é-A.; Remesar, X.; Foz, M.àr.; Alemany, M.à 2002: Pharmacological approaches for the treatment of obesity. Drugs 62(6): 915-944
Tamargo, J.; Caballero, R.; Delpón, E. 2004: Pharmacological approaches in the treatment of atrial fibrillation. Current Medicinal Chemistry 11(1): 13-28
Appolinario, J.C.; McElroy, S.L. 2004: Pharmacological approaches in the treatment of binge eating disorder. Current Drug Targets 5(3): 301-307
Thibaud, D.; Guyonnet, J.; Toutain, P.L. 2003: Pharmacological approaches of dose determination with tiludronate for use in the horse. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 200-201
King, M.; Rubin, B.K. 2002: Pharmacological approaches to discovery and development of new mucolytic agents. Advanced Drug Delivery Reviews 54(11): 1475-1490
Magyar, K.; Pálfi, M.; Tábi, T.; Kalász, H.; Szende, B.; Szöko, E. 2004: Pharmacological aspects of (-)-deprenyl. Current Medicinal Chemistry 11(15): 2017-2031
Müller-Peddinghaus, R. 1999: Pharmacological aspects of 5-lipoxygenase inhibition. Advances in Experimental Medicine and Biology 447: 117-121
Ichihara, K. 2000: Pharmacological aspects of HMG-CoA reductase inhibitors. Japanese Journal of Pharmacology 82(Suppl 1): 15P
Ozaki, M. 2001: Pharmacological aspects of a Chinese herb and Persimmon Tannin in the prevention of experimental hytertensive stroke. Mori, Akitane, Satoh, Tetsuo Emerging Drugs Molecular aspects of Asian medicine 69-77
Korstanje, C. 2001: Pharmacological aspects of alpha1-adrenoceptor antagonists in lower urinary tract symptoms. Drugs of Today 37(Suppl D): 17-21
Ishikawa, F.; Ohguro, H.; Maruyama, I.; Takano, Y.; Yamazaki, H.; Metoki, T.; Miyagawa, Y.; Sato, M.; Mamiya, K.; Nakazawa, M. 2003: Pharmacological aspects of nilvadipine-induced preservation of retinal degeneration in RCS rat analyzed by mRNA profiling assay. Kaneko, Akimichi The neural basis of early vision: 164-167
Sedlacek, H.H. 2001: Pharmacological aspects of targeting cancer gene therapy to endothelial cells. Critical Reviews in Oncology/Hematology 37(3): 169-215
Logan, M.A.; Heaton, W.L.; Ramoz Leslie, G.R.; Stormann, T.M.; Hammerland, L.G. 1999: Pharmacological assessment of mGluR5 in rat cortical astrocytes using intracellular calcium mobilization assays. Society for Neuroscience Abstracts 25(1-2): 1231
Claytor, R.; Diz, D.I.; Ferrario, C.M.; Ganten, D.; Aileru, A.A. 2001: Pharmacological assessment of nicotinic synaptic transmission in the superior cervical ganglia isolated from 27 transgenic rats. FASEB Journal 15(4): A474
Crandall, C.G.; Yen, T.C.; Shibasaki, M. 1999: Pharmacological assessment of the venoarteriolar response. FASEB Journal 13(4 Part 1): A433
Tanaka, T.; Li, Z.; Hiraizumi, Y.; Yamamoto, H.; Suzuki, F.; Israilova, M.; Muramatsu, I. 2003: Pharmacological assessment of tissue segment binding to detect native alpha1-adrenoceptor in rat thoracic aorta and tail artery. Journal of Pharmacological Sciences 91(Suppl I): 238P
Vergara, G.; Catanzariti, D.; Cozzi, F.; Accardi, R.; Spagnolli, W.; Cammilli, L. 1999: Pharmacological atrial defibrillation via temporarily occluded coronary sinus First preliminary experience. Circulation 100(18): 1; 501
Howard, M.O. 2000: Pharmacological aversion treatment of alcohol dependence Production of conditioning. Alcoholism Clinical and Experimental Research 24(5 Suppl): 79A
Nagai, H.; Kido, H.; Shinyama, H.; Egi, Y.; Akira, T.; Kitada, Y. 2004: Pharmacological bases of Lipo-PGE1 for amelioration of peripheral circulatory disorders. Journal of Pharmacological Sciences 94(Suppl 1): 103P
Sachs, G.; Shin, J.M.o 2002: Pharmacological basis for different rates of recovery of acid secretion after PPI treatment. Gastroenterology 122(4 Suppl 1): A 47
Ghayur, M.N.; Gilani, A.H.; Awais, M. 2004: Pharmacological basis for the cardiodepressant and sialogogue effects of betel nut. Naunyn-Schmiedeberg's Archives of Pharmacology 369(Suppl 1): R167
Gilani, H.; Jabeen, Q.; Aziz, N. 2003: Pharmacological basis for the ethnobotanical use of Lavandual stoechas in hypertension. Ethnicity and Disease 13(Suppl 2): S2 174-S2 175
Rosenkranz, S.; Boehm, M. 2000: Pharmacological basis of the circulation-stimulating effect of champagne. Deutsche Medizinische Wochenschrift 125(Suppl 1): S17
Zunino, F.; Perego, P. 1999: Pharmacological basis of the efficacy of topotecan in the treatment of ovarian cancer. Tumori 85(3 Suppl 1): S31-S33
Arai, Y.ichiro; Nakagawasai, Osamu; Fang, Yang Il; Hozumi, Soichi; Momose, Kazutaka; Yasuhara, Hajime; Tadano, Takeshi 2004: Pharmacological behaviours and MAO in olfactory bulbectomized mice. Journal of Pharmacological Sciences 94(Suppl 1): 165P
Li, Y.J.; Ji, Y.H. 2001: Pharmacological binding of BmK I and BmK IT2, two types of scorpion neurotoxins on cockroach nerve cord synaptosomes. Toxicon 39(2-3): 166
Settle, S.H.; Yamaguchi, H.; Bogatcheva, G.; Goldenring, J.; Coffey, R. 2002: Pharmacological blockade of EGFR signaling in MT-TGFalpha mice Further support for EGFR signaling in the pathogenesis of Menetriers disease. Gastroenterology 122(4 Suppl 1): A-252
Secondo, A.; Cataldi, M.; Taglialatela, M.; Giorgio, G.; Di Renzo, G.F.; Annunziato, L. 2000: Pharmacological blockade of the ERG K+ and ICRAC channels exerts opposite effects on i oscillations in GH3 cells. European Journal of Neuroscience 12(Suppl 11): 386
Morello, J.P.; Petäjä-Repo, U.E.; Bichet, D.G.; Bouvier, M. 2000: Pharmacological chaperones: a new twist on receptor folding. Trends in Pharmacological Sciences 21(12): 466-469
Kempsill, F.E.J.; Mcculloch, K.M.; Osipenko, O.N.; Gurney, A.M. 1999: Pharmacological characterisation of IKN in the rabbit pulmonary artery. Biophysical Journal 76(1 Part 2): A292
Shabbir, M.; Thompson, C.; Mikhailidis, D.; Morgan, R.; Burnstock, G. 2004: Pharmacological characterisation of P2-purinergic receptor mediated apoptosis in hormone refractory prostate cancer. European Urology Suppls 3(2): 147
Larsson, K.P.; Hansen, A.J.; Dissing, S. 1999: Pharmacological characterisation of P2Z purinoceptors in human SH-SY5Y neuroblastoma cells. Society for Neuroscience Abstracts 25(1-2): 460
Hay, D.L.; Howitt, S.G.; Conner, A.C.; Smith, D.M.; Poyner, D.R. 2002: Pharmacological characterisation of RAMP2/CL and RAMP3/CL adrenomedullin receptors with adrenomedullin22-52 and CGRP8-37. British Journal of Pharmacology 137(Proceedings Suppl): 16P
Hermann, B.; Landgraf, R.; Keck, M.; Wigger, A.; Morrow, A.L.; Holsboer, F.; Rupprecht, R. 1999: Pharmacological characterisation of cortical gamma-aminobutyric acid type A -receptors in two Wistar rat lines selectively bred for high- and low-anxiety-related behavior. Society for Neuroscience Abstracts 25(1-2): 1479
Lamb, H.; Benwell, K.R.; Revell, D.F.; Read, S.; Sheardown, M.J.; Porter, R.H.P. 1999: Pharmacological characterisation of human A1 and A2A receptors co-expressed with Galpha16 in CHO-K1 cells using a fluorimetric imaging plate reader. British Journal of Pharmacology 128(Proceedings Suppl ): 131P
Randall, V.A.; Patel, H.; Quinn, M.; Lamb, H.; Revell, D.F.; Benwell, K.R.; Croucher, M.J.; Palmer, A.M.; Sheardown, M.J.; Porter, R.H.P. 2000: Pharmacological characterisation of human adenosine A2B receptors co-expressed with Galpha16 in CHO-K1 cells. British Journal of Pharmacology 131(Proceedings Suppl December): 185P
Choppin, A.; Hegde, S.S.; Eglen, R.M. 1999: Pharmacological characterisation of muscarinic receptors in dog ciliary smooth muscle. British Journal of Pharmacology 126(Proceedings Suppl ): 93P
Choppin, A.; Eglen, R.M. 2000: Pharmacological characterisation of muscarinic receptors in feline and human isolated ciliary smooth muscle. British Journal of Pharmacology 129(Proceedings Suppl): 206P
Choppin, A.; Eglen, R.M. 2001: Pharmacological characterisation of muscarinic receptors in human isolated ciliary smooth muscle. Life Sciences 68(22-23): 2633
Eglen, R.M.; Choppin, A. 2001: Pharmacological characterisation of muscarinic receptors in mouse urinary bladder smooth muscle. Life Sciences 68(22-23): 2634
Brough, S.J.; Jerman, J.C.; Porter, R.; Martin, J.; Pilleux, J.P.; Smart, D. 2001: Pharmacological characterisation of orexin receptor subtype selective ligands. British Journal of Pharmacology 134(Proceedings Suppl): 41P
Fazal, A.; Parker, F.; Palmer, A.M.; Croucher, M.J. 2002: Pharmacological characterisation of positive modulatory metabotropic glutamate autoreceptors in the rat cerebral cortex. British Journal of Pharmacology 135(Proceedings Suppl): 90P
Woods, C.M.; Toouli, J.; Saccone, G.T.P. 2002: Pharmacological characterisation of purinergic P1 receptors in duodenum longitudinal smooth muscle of the Australian possum. Gastroenterology 122(4 Suppl 1): A-258
Bahra, P.; Poll, C.T.; Westwick, J.; Li, S.W. 2002: Pharmacological characterisation of receptor-mediated and store-dependent calcium influx in the human promyelocytic leukaemic cell line. British Journal of Pharmacology 135(Proceedings Suppl): 333P
Peckham Cooper, A.B.; Af Forselles, K.J. 2002: Pharmacological characterisation of the longitudinal female rat urethra in vitro. British Journal of Pharmacology 135(Proceedings Suppl): 14P
Martin, E.; Pavia, J.; Montiel, M.; Morell, V.; Sanchez, D.L.C.esta, F.; Jimenez, E. 2000: Pharmacological characterisation of the muscarinic receptors in thyroid epithelial cells. Methods and Findings in Experimental and Clinical Pharmacology 22(6): 514
Miller, J.C.; Tse, H.W.; Monaghan, D.T.; Jane, D.E. 2002: Pharmacological characterisation of the subunit selective NMDA receptor antagonist PPDA on neonatal rat motoneurones. British Journal of Pharmacology 135(Proceedings Suppl): 88P
Howson, P.A.; Tse, H.W.; Crossley, C.C.; Jane, D.E. 2002: Pharmacological characterisation of three 2-oxopyridylalanine analogues on glutamate receptors expressed on neonatal rat motoneurones. British Journal of Pharmacology 135(Proceedings Suppl): 91P
Loescher, W.; Lehmann, H.; Potschka, H.; Behl, B.; Seemann, D.; Teschendorf, H.J.; Hofmann, H.P.; Treiber, H.T.; Szabo, L.; Lubisch, W.; Hoeger, T.; Lemaire, H.G.; Gross, G. 1999: Pharmacological characteristics and anticonvulsant effect of novel non-NMDA receptor antagonists. Epilepsia 40(Suppl 2): 130-131
Minoura, H.; Takeshita, S.; Ita, M.; Hirosumi, J.; Mabuchi, M.; Kawamura, I.; Nakajima, S.; Nakayama, O.; Kayakiri, H.; Oku, T.; Ohkubo-Suzuki, A.; Fukagawa, M.; Kojo, H.; Hanioka, K.; Yamasaki, N.; Imoto, T.; Kobayashi, Y.; Mutoh, S. 2004: Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. European Journal of Pharmacology 494(2-3): 273-281
Kostromitinow, N.A. 2003: Pharmacological characteristics of aethonitum. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 238-239
Thomas, J.M.; Churchill, G.C.; Lad, C.J.; Galione, A. 2000: Pharmacological characteristics of cADPR binding to sea urchin egg homogenate. British Journal of Pharmacology 129(Proceedings Suppl): 237P
Tsushima, H.; Mori, M. 2002: Pharmacological characteristics of central bombesin receptor involved in hypothermia, antidiuresis and anorexia. Japanese Journal of Pharmacology 88(Suppl 1): 137P
Mukai, S.; Shoge, K.; Shinya, M.; Mishima, H.K.; Ishihara, K.; Sasa, M. 2000: Pharmacological characteristics of ionotropic glutamate receptor subtypes in cultured rat retinal ganglion cells - a whole-cell patch clamp study. Japanese Journal of Pharmacology 82(Suppl 1): 142P
Takeda, H.; Tsuji, M.; Inazu, M.; Hayashi, M.; Yamada, T.; Miyamoto, J.; Matsumiya, T. 2001: Pharmacological characteristics of novel anti-depressive substance extracted from Perilla Herba. Japanese Journal of Pharmacology 85(Suppl 1): 48P
Torrado, J.; Carrascosa, C. 2003: Pharmacological characteristics of parenteral IGF-i administration. Current Pharmaceutical Biotechnology 4(2): 123-140
Bousquet, P.; Gayet, J-Louis. 2003: Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor. Therapie 58(2): 113-121
Taniguchi, H.; Tanaka, Y.; Tanaka, H.; Shigenobu, K. 1999: Pharmacological characteristics of thapsigargin-induced Ca2+ entry leading to endothelium-dependent vasorelaxation of guinea-pig thoracic aorta. Japanese Journal of Pharmacology 79(Suppl 1): 172P
Watanabe, T. 2002: Pharmacological characteristics of the radical scavenger edaravone. Japanese Journal of Pharmacology 88(Suppl 1): 22P
Birnbacher, R.; Pollak, A.; Amann, G.; Breitschopf, H.; Wolf, H.; Heinz Erian, P. 1999: Pharmacological characterization and cellular localization of insulin-like growth factor-I binding to human placenta during the course of pregnancy and at term. Pediatric Research 45(4 Part 2): 85A
Chan, Y.n, L.; Dong, Ke; Ferguson, William, B.; Macgregor, Gordon, G.; Hebert, Steven, C.; Giebisch, Gerhard 2001: Pharmacological characterization and comparison of Kir11b and Kir61 potassium channels cloned from rat kidney. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 28A
Zapata-Sudo,G.; Pereira,S.L.; Beiral,H.J.V.; Kummerle,A.E.; Raimundo,J.M.; Antunes,F.; Sudo,R.T.; Barreiro,E.J.; Fraga,C.A.M. 2010: Pharmacological characterization of -3,4-methylenedioxybenzoylhydrazide a novel muscarinic agonist with antihypertensive profile. American Journal Of Hypertension: 2, 135-141
Hirose, H.; Kimura, T.; Fujikawa, T.; Numazawa, T.; Aoki, I.; Ohtake, N.; Nishikibe, M.; Mase, T.; Noguchi, K. 2001: Pharmacological characterization of -N- piperidin-4-yl-2-. Life Sciences 68(22-23): 2627
Lim, Y.; Skaar, T.C.; Weatherman, R.V.; Desta, Z.; Bermes, A.; Flockhart, D.A.; Johnson, M.D. 2004: Pharmacological characterization of 4-hydroxy-N-desmethyl-tamoxifen and 4-hydroxy-tamoxifen. Clinical Pharmacology and Therapeutics 75(2): P19
Matsumoto, M.; Togashi, H.; Mori, K.; Ohashi, S.; Ueno, K.I.; Saito, H.; Yoshioka, M. 2001: Pharmacological characterization of 5-HT receptors involved in fluvoxamine-mediated synaptic transmission in the rat hippocampal CA1 and CA3 fields. Japanese Journal of Pharmacology 85(Suppl 1): 271P
Chen, J.; Krauss, A.H.P.; Gil, D.W.; Protzman, C.E.; Wheeler, L.A.; Woodward, D.F. 2001: Pharmacological characterization of AGN 192024 in ocular and non-ocular preparations and its relation to the prostamides. IOVS Investigative Ophthalmology and Visual Science 42(4): S832
Stec, D.; Sigmund, C. 2000: Pharmacological characterization of BPH2 genetically hypertensive mice. Journal of Hypertension 18(Suppl 4): S170
Zhang, X.F.; Iwamuro, Y.; Okamoto, Y.; Miwa, S.; Masaki, T. 1999: Pharmacological characterization of Ca2+ entry channels in ET-1-induced contraction in rat aorta using LOE 908 and SKF 96365. Japanese Journal of Pharmacology 79(Suppl 1): 115P
Takazawa, A.; Yamazaki, O.; Kinoshita, M.; Ishida, N.; Kato, N.; Yamauchi, T. 2000: Pharmacological characterization of EEG spikes and seizures induced by a specific calcium-permeable AMPA receptor antagonist, 1-naphthylacetyl spermine. Epilepsia 41(Suppl 9): 54
Sato, A.; Aoki, I.; Fujikawa, T.; Numazawa, T.; Kimura, T.; Sasaki, K.; Mase, T.; Tomimoto, K.; Noguchi, K. 1999: Pharmacological characterization of J-104129, a novel muscarinic M3 receptor antagonist with high selectivity over M2 receptors. Japanese Journal of Pharmacology 79(Suppl 1): 48P
Chalon, S.; Halldin, C.; Tarkiainen, J.; Emond, P.; Hall, H.; Vercouillie, J.; Garreau, L.; Besnard, J.C.; Guilloteau, D. 2001: Pharmacological characterization of MADAM A potent and selective ligand for the serotonin transporter. Journal of Nuclear Medicine 42(5 Suppl): 250P
Van Wauwe, J.; Aerts, F.; Cools, M.; Goossens, J.; Hermans, B.; Van Genechten, H.; Van Nyen, G. 2000: Pharmacological characterization of R146225, a novel inhibitor of interleukin-5 biosynthesis. Inflammation Research 49(Suppl 2): S89
Behm, D.J.; Herold, C.L.; Ohlstein, E.H.; Knight, S.D.; Dhanak, D.; Douglas, S.A. 2002: Pharmacological characterization of SB-710411 -Cpa-amide, a novel peptidic urotensin-II receptor antagonist. British Journal of Pharmacology 137(4): 449-458
Ibba, M.; Calo', G.; Guerrini, R.; Toth, G.; Lambert, D.G. 2003: Pharmacological characterization of UFP-101, a novel radioligand selective for the nociceptin/orphanin FQ receptor. British Journal of Pharmacology 138(Proceedings Suppl): 222P
Van Der Giet, M.; Cinkilic, O.; Jankowski, J.; Schlueter, H.; Tepel, M.; Zidek, W. 1999: Pharmacological characterization of a new P2X-receptor regulating perfusion pressure in the kidney. Kidney and Blood Pressure Research 22(4-6): 381-382
Van Der Giet, M.; Cinkilic, O.; Jankowski, J.; Schlueter, H.; Tepel, M.; Zidek, W. 1999: Pharmacological characterization of a new P2X-receptor subtype mediating perfusion pressure in the isolated perfused kidney. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 358A
Kajita, S.; Ito, C.; Isobe, Y.; Fukushima, K. 1999: Pharmacological characterization of a novel 5-HT4 receptor agonist, TS-951 in vitro. Japanese Journal of Pharmacology 79(Suppl 1): 206P
Douglas, S.A.; Disa, J.; Naselsky, D.; Romanic, A.; Louden, C.; Ao, Z.; Foley, J.J.; Elshourbagy, N.A.; Sarau, H.M.; Ames, R.S.; Ohlstein, E.H.; Willette, R.N. 1999: Pharmacological characterization of a novel human G-protein-coupled receptor with specificity for the vasoactive peptide human urotensin-II. Circulation 100(18): 1; 6
Westlin, W.F.; Griggs, D.W.; Engleman, V.W.; Keene, J.L.; Duffin, T.D.; Settle, S.L.; Nickols, M.A.; Hollister, B.A.; Knoerzer, D.L.; Meyer, D.M.; Pegg, J.A.; Ruminski, P.G.; Rogers, T.E.; Russell, M.A.; Nickols, G.A. 2001: Pharmacological characterization of a novel orally active angiogenesis inhibitor, S-137 An antagonist of the integrin alphavbeta3. Proceedings of the American Association for Cancer Research 42: 588
Inomata, N.; Ogata, A.; Mizuno, A.; Kamei, T.; Takiguchi, C.; Oka, N.; Yamaki, A.; Matsui, N.; Nishimura, M.; Hayashi, Y. 1999: Pharmacological characterization of a novel, selective and potent 5-HT2 receptor antagonist, SUN C5174. Japanese Journal of Pharmacology 79(Suppl 1): 185P